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Widmung 
 
Für meine Eltern.  
 
Einmal kommt der Moment, wenn du sagst: 
"Nun lass mich schon los. Ich kann selbst fliegen!" 
Oh, dann drück ich dich noch einmal geschwind. 
Hol tief Luft und geb dir ganz viel Rückenwind. 
Leise werde ich beten: "Gott behüt mein Kind!" 
 
Und dann öffne ich meine Arme. Und dann öffne ich meine Arme für dich! 
Gerhard Schöne 
 
 
 
 
In Erinnerung an Conny! 
 
Irgendwann heißt, es kann morgen geschehn  
und dass wir uns heut' das letzte Mal sehn.  
Drum, was du erlebst, erleb' es total,  
denn alles, alles gibt's ein letztes Mal.  
Alles, alles gibt's ein letztes Mal. 
 
Gerhard Schöne 
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1. Summary 
 
Ataxia Telangiectasia - an autosomal recessive, multisystem disorder - is characterized by 
progressive cerebellar ataxia, telangiectasia, immune defects and a predisposition to 
malignancy and was first described in 1926 by Syllaba and Henner (Syllaba, L., Henner, K. 
1926). The gene – Ataxia Telangiectasia Mutated (ATM) - was identified on chromosome 
11q22-23 and up to now more than 350 different mutations have been described. The ATM 
protein is a 350 kDa serine-threonine protein kinase that localizes mainly to the nucleus and 
plays a key role in the repair of DNA double strand breaks that are typically induced by ionizing 
radiation (IR). ATM is activated after IR-induced double strand breaks occur and subsequently 
phosphorylates many downstream targets that are involved in DNA damage repair 
mechanisms and cell cycle control. This activation cascade leads either to cell cycle arrest, 
repair of the DNA damage or induction of apoptosis. Disturbances in these mechanisms can 
result in an accumulation of DNA alterations that predispose the damaged cells to malignant 
transformation.  
Since 1991, ATM has been discussed as a susceptibility gene for breast cancer (Swift et al. 
1991), in particular the missense mutation c.7271T>G, p.Val2424Gly. For this missense 
variation a dominant-negative mechanism is described in the literature and in 2006 Waddell 
used expression profiles to discriminate c.7271T>G carriers from healthy controls (Chenevix-
Trench et al. 2002; Waddell et al. 2006). 
In the present study proteomics-based approaches in addition to different cell biological and 
biochemical investigations were used to elucidate the cellular reactions upon ionizing 
radiation of lymphoblastoid cell lines from A-T patients carrying different ATM-mutations with 
one AT patient homozygous for c.7271T>G, breast cancer patients heterozygous for 
c.7271T>G,  and healthy controls.  
FACS analysis could confirm already published data  for a higher susceptibility to cell death 
and G1 arrest (f.e. (Bakkenist und Kastan 2003) for the cell lines derived from breast cancer 
patients harboring the heterozygous c.7271T>G variant upon IR. In contrast the Western Blot 
analysis could not confirm the dominant negative effect that was postulated by Chenevix-
Trench and Waddell for the cell lines harbouring the heterozygous c.7271T>G substitution. In 
contrast to the published data the present study could show that downstream targets of ATM 
are still phosphorylated upon IR. The pedigree of the family A published 2002 by Chenevix-
Trench shows that the breast cancer is inherited within the same haplotype, so there could be 
other factors accounting for this phenotype. 
Two proteomics-based approaches, DIGE analysis and SWATH acquisition, were used to 
investigate the cellular response upon ionizing radiation for all cell lines. Two members of the 
ATM pathway –SMC1A and MRE11 – were significantly downregulation in the healthy control 
cell lines, with MRE11 also downregulated in the AT cell lines. A shift in the 2D gel of the 
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phosphorylated proteins SMC1A and MRE11 would explain that downregulation upon 
irradiation. Additionally, the AT patients and control cell lines showed an upregulation of 
RAD23B – a protein involved in Nucleotide Excision Repair (NER) – upon IR in the SWATH 
approach, which was not present in the cell lines derived from breast cancer patients. The 
upregulation of RAD23B was also found in the AT patient cell line in the DIGE analysis. This 
regulation of RAD23B gives a first hint to a restricted function of NER  and maybe DNA 
mismatch repair (MMR) in the cell lines derived from the breast cancer patients harbouring 
the c.7271T>G substitution. Additionally, the SWATH-MS approach showed a reduced 
regulation of proteins involved in NER and MMR in the c.7271T>G heterozygous cell lines 
compared to the controls. Therefore, these proteomics data show for the first time the 
postulated link between ATM and the MMR pathway ( (Romeo et al. 2011), which needs 
further investigation. 
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2. Zusammenfassung 
 
Ataxia telangiectasia  ist eine autosomal-rezessive vererbte Multisystemerkrankung, welche 
durch eine fortschreitende zerebelläre Ataxie, Teleangiektasien, Immundefekte und eine 
Prädisposition für Tumore gekennzeichnet ist. Sie wurde erstmals 1926 von Syllaba und 
Henner (Syllaba, L., Henner, K. 1926) beschrieben. Das Gen - Ataxia Telangiectasia Mutated 
(ATM) - liegt auf Chromosom 11q22-23 und bisher wurden mehr als 350 verschiedene 
Mutationen beschrieben. Das ATM-Protein ist eine 350 kDa Serin-Threonin-Proteinkinase, die 
hauptsächlich im Zellkern lokalisiert ist. ATM spielt eine Schlüsselrolle bei der Reparatur von 
DNA-Doppelstrangbrüchen, welche vor allem durch ionisierende Strahlung (IR) induziert 
werden. IR induzierte Doppelstrangbrüche führen zu einer Aktivierung von ATM, welches 
dann weitere Proteine - die an DNA-Reparaturmechanismen und Zellzykluskontrolle beteiligt 
sind – phosphorylieren kann. Diese Aktivierungskaskade führt entweder zum Zellzyklusarrest, 
zur Reparatur der DNA-Schäden oder zur Apoptose. Defekte in diesen Mechanismen können 
zu einer Anhäufung von Mutationen führen und somit zu einer möglichen Tumorentstehung 
beitragen.  
Seit 1991 wird ATM als möglicher Risikofaktor für Brustkrebs diskutiert (Swift et al. 1991), 
insbesondere die Missense-Mutation c.7271T> G, p.Val2424Gly. Für diese Missense-Variante 
wird in der Literatur ein dominant-negativer Effekt beschrieben, und Waddell verwendete 
2006 Expressionsprofile, um Mutationsträger der c.7271T>G-Variante von gesunden 
Kontrollen zu unterscheiden (Chenevix-Trench et al. 2002; Waddell et al. 2006). 
In der vorliegenden Arbeit wurden neben verschiedenen zellbiologischen und biochemischen 
Untersuchungen auch Proteomik-basierte Ansätze verwendet, um die zelluläre Reaktion 
verschiedener lymphoblastoider Zelllinien (AT-Patienten mit verschiedenen ATM-
Mutationen, eine AT-Patient homozygoten für c.7271T>G,  Brustkrebspatienten heterozygot 
für c.7271T> G und gesunde Kontrollen) auf ionisierende Bestrahlung zu untersuchen. 
Mittels FACS - Analysen konnte für die Zelllinien der Brustkrebspatienten nach Bestrahlung 
eine höhere Sterberate der Zellen sowie ein Arrest in der G1-Phase des Zellzyklus 
nachgewiesen – und somit bereits publizierte Daten  (u.a. Bakkenist und Kastan 2003) 
bestätigt – werden. Die ebenfalls durchgeführten Western Blots konnten den dominanten 
negativen Effekt, den Chenevix-Trench und Waddell für die heterozygote c.7271T> G 
Substitution postulierten, nicht bestätigen: Im Gegensatz zu den publizierten Daten konnte 
die vorliegende Arbeit zeigen, dass Downstream-Targets von ATM nach Bestrahlung weiterhin 
phosphoryliert werden. Der Stammbaum der Familie A, der 2002 von Chenevix-Trench 
veröffentlicht wurde, zeigt, dass der Brustkrebs innerhalb des gleichen Haplotyps vererbt 
wird, so dass auch andere Faktoren für diesen Phänotyp verantwortlich sein können. 
Um die zelluläre Reaktion auf ionisierende Bestrahlung bei allen Zelllinien zu untersuchen 
wurden zwei Proteomik-basierte Ansätze, DIGE und SWATH, verwendet. Zwei Downstream-
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Targets von ATM -SMC1A und MRE11- waren in den gesunden Kontrollzelllinien signifikant 
herunterreguliert, wobei MRE11 ebenfalls in den AT-Zelllinien herunterreguliert war. Eine 
möglicher Erklärung hierfür ist eine Phosphorylierung von MRE11 und SMC1A und demzufolge 
eine Verschiebung der Proteinspots auf dem 2D-Gel. Zusätzlich zeigten die Zelllinien der AT-
Patienten und Kontrollen eine Hochregulation von RAD23B - einem Protein, das am 
Nucleotide Excision Repair (NER) Signalweg beteiligt ist. Diese Regulation konnte jedoch bei 
den Zelllinien der Brustkrebspatienten nicht nachgewiesen werden. Zusätzlich konnte eine 
Hochregulation von RAD23B auch in den Zelllinien der AT-Patienten mittels DIGE beobachtet 
werden. Dies ist ein erster Hinweis auf eine eingeschränkte Funktion des NER-Signalwegs und 
möglicherweise auch des MMR-Signalwegs in den Zelllinien der Brustkrebspatienten. 
Zusätzlich zeigten die SWATH-MS-Daten für die Zelllinien der Brustkrebspatienten eine 
reduzierte Regulation von Proteinen, die am NER- und MMR-Signalweg beteiligt sind. Mittels 
dieser Proteomdaten konnte erstmals die bereits publizierte Verbindung zwischen ATM und 
dem MMR-Signalweg ((Romeo et al. 2011)) auf zellulärer Ebene nachgewiesen werden, was 
durch weitere Experimente näher untersucht werden sollte. 
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3. Introduction  
3.1. Ataxia Telangiectasia 
The central theme of my thesis concerns Ataxia Telangiectasia (A-T), a rare autosomal 
recessive disorder, the symptoms of which were first described in 1926 by Syllaba and Henner 
(Syllaba, L., Henner, K. 1926). Fifteen years later, Louis-Bar reported a family with related 
symptoms, before Boder and Sedgwick recognized A-T as a distinct clinical entity in 1957 
(BODER und SEDGWICK 1958; Louis-Bar 1941).  
A-T is characterised by a complex phenotype involving the nervous, immune and reproductive 
systems. A-T patients show progressive cerebellar ataxia, oculocutaneous telangiectasia, 
radiosensitivity and a predisposition to lymphoid malignancies and immunodeficiency. In 
Germany, there are approximately 200 reported cases, which corresponds to an estimated 
prevalence of 1:400,000. 
Classical A-T is diagnosed in children between ages one and four years who show progressive 
cerebellar dysfunction, that can be present as gait and truncal ataxia, head tilting, slurred 
speech and oculomotor apraxia. The diagnosis is confirmed by measuring the serum-alpha-
fetoprotein (AFP) level, which is elevated > 10 ng/mL. Also commonly used is the colony 
survival assay – a radiosensitivity assay that determines the survival rate of cultured 
lymphoblastoid cells from A-T patients after irradiation with 1 Gy (Sun et al. 2002) – or 
karyotyping to determine chromosomal breaks or translocations, like the common 7;14 
translocation. The most sensitive and specific test for establishing a diagnosis of A-T is 
immunoblotting of the ATM protein (Chun et al. 2003). About 90% of the patients do not show 
detectable ATM protein in this test, around 10% have trace amounts of protein and ~1% show 
normal ATM protein levels but no kinase activity (so called “kinase-dead”). To measure the 
activity of the ATM protein usually immunoblotting for ATM-dependent phosphorylation 
target proteins such as p53 (Ser15), SMC1 (Ser966) or ATM itself (Ser1981) is employed. 
Therefore, lymphoblastoid cells isolated from A-T patients are irradiated to generate DNA 
double-strand breaks and, consequently, to activate ATM. After an incubation period of 30 – 
60 min, the cells are harvested and the phosphorylation status of the downstream substrate 
is determined. In 2008 and 2009, two groups described a new method to measure the 
phosphorylation of H2AX or SMC1 by flow cytometry (Nahas et al. 2009; Porcedda et al. 2008). 
Another way to validate the A-T diagnosis is sequence analysis to find the underlying mutation 
in the ATM gene.  
Classical A-T symptoms vary slightly in the late stages of the disease. However, the time of 
onset and rate of progression of symptoms can vary considerably. The presenting symptom in 
classical A-T patients is progressive ataxia, which manifests itself when the child begins to 
walk. Patients show an ataxic gait and truncal movements and become confined to a 
wheelchair by the end of the first decade of their life. The speech becomes slurred and they 
are not able to follow an object across visual fields (oculomotor apraxia). These neurological 
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symptoms are due to the progressive cortical cerebellar degeneration that involves mainly the 
Purkinje and granular cells. The second presenting symptom is telangiectasia, which has a later 
onset and is usually observed between two and eight years of age. The dilation of small blood 
vessels occurs commonly in the eyes and also in the skin – mainly in the butterfly area of the 
face - and in the ears (BODER 1985). Compared to the neurological features, the 
immunodeficiencies vary much more and are present in 60% - 80% of cases. Affected patients 
suffer an excess of bacterial sinopulmonary infections like sinusitis, bronchitis, pneumonia and 
later on pulmonary fibrosis. The serum concentrations of IgA, IgE and IgG2 are reduced and 
the patients show peripheral lymphopenia and a small embryonic-like thymus (McFarlin et al. 
1971; McFarlin et al. 1972). Gamma/delta T-cell levels are usually elevated which is typical for 
an incomplete T-cell development. Peterson and Funkhouse proposed that these can be 
explained by a defect in genetic recombination thus preventing the switch from immature T-
cells with gamma/delta chains to mature T-cells with alpha/beta chains (Peterson und 
Funkhouser 1990). In addition to immunodeficiency, classical A-T patients show a strong 
predisposition to malignancy. Younger children tend to have acute lymphoblastic leukemia 
(ALL) of T-cell origin, older children more aggressive T-cell leukemia and older A-T patients 
show especially ovarian cancer, breast cancer, gastric cancer, melanoma and sarcoma. In 
addition to these lead symptoms, A-T is also characterized by many additional features that 
are more variable in their appearance but can help to confirm the diagnosis. These include 
premature aging with strands of gray hair, endocrine abnormalities, like unusual types of 
diabetes mellitus (hyperinsulinism, hyperglycemia and no glycosuria or ketosis and peripheral 
insulin-resistance), growth retardation and hypogonadism. Nevertheless A-T patients show 
typically a normal intelligence with some learning difficulties due to their slow motor and 
verbal responses.  
Since the 1980th several reports about A-T variants have been published. Patients, for 
example, show milder clinical symptoms with a later onset (McConville et al. 1996; Stankovic 
et al. 1998; Saviozzi et al. 2002), a combination of A-T and Nijmegen breakage syndrome 
symptoms (Curry et al. 1989; Gilad et al. 1998) or atypical symptoms (progressive ataxia but 
no telangiectasia, normal AFP and immune function) with mutations in the ATM gene and 
changes in ATM kinase activity (Saunders-Pullman and Gatti 2009; Alterman et al. 2007).  
 
3.2.  ATM Gene 
The ATM-gene consists of 160 kb genomic DNA, which is transcribed in a mRNA with 66 exons 
and encodes a 350 kDa protein kinase that is mainly located in the nucleus (Uziel et al. 1996).  
In 1988, Gatti and colleagues used genetic linkage analysis to localize the Ataxia-Telangiectasia 
gene on the long arm of chromosome 11 (11q22-23) (Gatti et al. 1988). In 1995, Savitsky et al. 
identified one gene in this region, which was mutated in all patients with Ataxia-Telangiectasia 
symptoms – the ATM-gene (Ataxia Telangiectasia Mutated) (Savitsky et al. 1995) and about 
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90% of the ATM sequence variants are detected in the coding region of the gene. Classical A-
T phenotypes are associated with homozygosity or compound heterozygosity for two 
deleterious ATM mutations (Gatti et al. 1999).  
To date there are 706 different mutations known (The Human Mutation Database; 03.2013) 
and 32% of them are nonsense or missense mutations that can lead to a premature 
degradation or destabilisation of the resulting protein. 27% of the mutations are small 
deletions, insertions or indels. There are 95 different mutations known to affect splice or 
regulatory sites of the ATM gene, which may give rise to “leaky splicing” whereby a small 
amount of intact ATM protein is expressed. The remaining 27% are gross deletions, insertions, 
duplications or complex rearrangements.  
 
3.3.  ATM protein  
The ATM protein is a serine/threonine protein kinase that is evolutionarily conserved and 
related to the PI3K-like protein kinase family (Phosphatidylinositide-3-kinase; PIKKs). All these 
proteins are grouped together based on similarities of a conserved domain in their C-terminus. 
In addition to ATM, two other PIKK family members show substantial sequence similarity and 
related functions – ATR (Ataxia Telangiectasia and Rad3 related) and DNA-PKCS (DNA-
Phosphatidylinositide kinase) (Durocher und Jackson 2001). Low resolution cryoelectron 
microscopy data of DNA-PKcs showed tandem HEAT repeats in the N-terminus that form a ring-
like structure with a “head or crown-like” structure on top of it. This “crown” contains the FAT, 
PI3-kinase and FATC domain and the ring-like structure has a cavity that can accommodate 
the ends of a DNA molecule. The N-terminus is an important interaction surface of ATM, for 
example for NBS1 or chromatin. FAT and FATC domain - that are located in the C-terminus – 
are involved in the regulation of the kinase activity of PIKKs. The FAT domain can interact with 
the PI3 kinase domain to stabilize the C-terminal region of ATM itself and is also a hot spot for 
posttranslational modifications like acetylation, phosphorylation or sumolyation. The PI3 
kinase domain is located close to the C-terminus between the FAT and FATC domain. This 
region has a protein kinase activity and phosphorylates a large subset of proteins especially 
on ST/Q motifs (Llorca et al. 2003; Rivera-Calzada et al. 2005). One of the first substrates of 
ATM to be identified in vitro and in vivo was p53. The stabilization and activation of p53 is 
defective in A-T patients, which leads to a defective G1-S-checkpoint (Kastan et al. 1992).  
More recently, it has been proposed that ATM functions as a redox sensor and may regulate 
global cellular responses to oxidative stress or a non-nuclear function as a member of the 
NFκB-pathway and an association with peroxisomes and endosomes (Wu et al. 2006; Lim et 
al. 1998; Watters et al. 1999; Guo et al. 2010). But the most common and best investigated 
function of the ATM protein is its role in the DNA damage machinery, the control of the cell 
cycle and the involvement in apoptosis.  
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The activation of ATM occurs after DNA damage in a MRN (MRE11-RAD50-NBS1)-dependent 
manner, the ATM dimer is separated in monomers and many posttranslational modifications 
occur (Bakkenist und Kastan 2003). MRN is a complex of three different proteins, namely  
MRE11, NBS1 and RAD50; it is required for optimal induction of ATM kinase activity. NBS1 
binds with the forkhead-associated (FHA) and the BRCA1 C-terminus (BRCT) domain directly 
on the active histone H2AX (γ-H2AX) to recruit the MRN complex via binding of MRE11 to the 
site of the DNA damage (Jager et al. 2001; Paull und Lee 2005). Also ATM is arriving at the DNA 
damage site through the interaction with MDC1, which forms an interaction platform by 
binding γ-H2AX via its BRCT domain, ATM via its FHA domain, NBS1 and other downstream 
targets (Lou et al. 2006). It is likely that ATM is activated at least partially through the initial 
relaxation of the chromatin structure by the break. But for complete activation ATM has to be 
localized to the DNA double strand break and it undergoes several posttranslational 
modifications (Berkovich et al. 2007). In 2003, Bakkenist and Kastan first showed the 
autophosphorylation on Ser1981 and monomerization of ATM as an important step in the 
activation process (Bakkenist und Kastan 2003). Therefore, the detachment of protein 
phosphatase 2 (PPA2) is needed and the following auto-phosphorylation is responsible for the 
dissociation of the dimeric inactive ATM to an active monomeric form. In 2006, Kozlov et al. 
showed the functional significance of two other phosphorylation sites in ATM – Ser367 and 
Ser1893 (Kozlov et al. 2006). But beside these phosphorylation sites, Sun et al. could 
demonstrate that ATM also undergoes acetylation by the TIP60 histone acetyltransferase at 
the Lys3016 residue (Sun et al. 2007; Sun et al. 2005). The fully activated ATM is able to 
phosphorylate a series of downstream targets that are involved in DNA repair, cell-cycle 
checkpoint activation and transcription. The first substrate of ATM was published in 1998 by 
three different groups (Banin et al. 1998; Canman et al. 1998; Khanna et al. 1998). They could 
show that the activated ATM is able to phosphorylate the tumor suppressor p53 on Ser15 in 
response to DNA damage. ATM also phosphorylates the p53-asccoiated protein HDM2 
(human double minute-2) on Ser403 and mediates the CHK2 (checkpoint kinase 2) 
phosphorylation of HDM2 on Ser342 and Ser367. The three phosphorylation events and the 
auto-polyubiquitination of HDM2 lead to the degradation of HDM2 and the subsequent 
release and stabilization of phosphorylated and active p53. p53 can lead to growth arrest (via 
p21, GADD45 or 14-3-3δ), DNA repair (via GADD45, XPC or p48) or apoptosis (via Bax, Fas, 
Puma or Noxa) (Lavin 2008). Another ATM-dependent downstream event is the 
phosphorylation of histone H2AX on its C-terminal end in the chromatin regions surrounding 
DNA double strand breaks. γH2AX foci are initially present as small compact structures, close 
to the DNA damage and quickly spread along the chromatin up to 2 Mb away from the break. 
They act as an assembly platform to facilitate the accumulation of DNA repair and chromatin 
remodelling proteins near the damaged site. Ubiquitination by UBC13 – an ubiquitin-
conjugating enzyme - mediates the TIP60-dependent acetylation and, therefore, the release 
of γH2AX from damaged chromatin (Pilch et al. 2003; Ikura et al. 2007). Another substrate of 
ATM is MDC1, which binds to γH2AX via its BRCT domain and acts as a platform for DNA repair 
proteins, too. Furthermore, ATM is also required to phosphorylate NBS1 on Ser278 and Ser343 
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and to mediate the ATM-dependent phosphorylation of SMC1 on Ser957 and Ser966 for 
activation of the S-Phase checkpoint, cell survival and maintaining the integrity of the genome 
(Gatei et al. 2000; Kitagawa et al. 2004). Activated ATM and NBS1 are important for the repair 
process during Homologous Recombination (HR).  
 
3.4. Genomic instability 
3.4.1. DNA damage 
The DNA is a rich source of genetic information in each living cell and its integrity and stability 
is essential for life. DNA damage is unavoidable and arises by spontaneous alterations of the 
chemical bonds in the DNA through endogenous cellular processes like copying errors 
introduced by DNA polymerase, oxidations or hydrolysations (deamination, depurination) 
from reactive oxygen species or exogenous agents like UV-light, ionizing radiation or 
chemicals. If DNA sequence changes are not repaired, both proliferating and quiescent cells 
might accumulate mutations and function no longer properly. Thus, the prevention of DNA 
damage in all types of cells is important for cell survival and several cellular mechanisms for 
repairing damaged DNA and correcting sequence errors have evolved. Because DNA plays an 
active and critical role in cell division, the control of DNA repair is closely tied to the regulation 
of the cell cycle. During the cell cycle, checkpoint mechanisms ensure that the DNA is intact 
before permitting replication and cell division to occur. Cells developed a number of processes 
to detect and repair the various types of alterations in the DNA and many of the proteins 
involved are highly conserved throughout evolution. Alterations in the DNA can range from 
single base mutations - that affect only one DNA strand - to breaks across both strands of the 
DNA – so-called double strand breaks. 
  
3.4.2. DNA Repair 
For single base mutations there are two common repair ways known. The first one is called 
Base Excision Repair (BER) and is commonly used to repair spontaneous DNA damage that can 
be caused by free radicals and other reactive species generated by metabolism, for example 
a deamination of 5-methyl cytosine to thymidine. DNA glycosylases flip the damaged base out 
of the helix and hydrolyse the bond that connects it to the sugar-phosphate-DNA backbone. 
An endonuclease cuts the DNA strand and the result is a single-stranded-gap, which is filled 
and sealed by a DNA polymerase and ligase. Humans have a large number of specific 
glycosylases and each of them is specific to certain types of base alterations. 
The second mechanism to repair point mutations is called Nucleotide Excision Repair (NER). 
This way to repair DNA damage is mainly used to fix DNA regions that contain chemically 
modified bases, which influence the normal shape of DNA locally, e.g., thymine-thymine-
dimers caused by UV-light. Special repair proteins recognize the DNA lesion and recruit 
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transcription factors that unwind and stabilize the DNA helix. Endonucleases cut the damaged 
strand on each side of the lesion and release the DNA fragment with the damaged bases. 
Afterwards, the gap is filled by a DNA polymerase and sealed by a DNA ligase.  
Another form of DNA damage are double strand breaks. They are caused by ionizing radiation 
(including X-ray and gamma-ray) and/or some anticancer-drugs (like bleomycin). These breaks 
are highly deleterious and an incorrect rejoining can lead to chromosomal rearrangements 
and translocations, which can produce a hybrid gene or inappropriate activation of genes. An 
exception is the immune system. The B and T cells are particularly susceptible to DNA 
rearrangements of their immunoglobulin or T-cell receptor genes. DNA double strand breaks 
can be repaired through one of the two following mechanisms – Non-Homologous-End-Joining 
(NHEJ) or Homologous Recombination. 
Non-homologous-end-joining (NHEJ) uses the fact that the movement of the DNA molecules 
in the protein-dense nucleus is fairly minimal and so in general the correct broken DNA ends 
can be joined together. But the repair process results in the loss of genetic material at the 
joining end and sometimes in translocations, if broken ends from different chromosomes are 
joined together. The rejoining of the non-homologous ends of two DNA molecules is 
processed by a complex of Ku- and DNA-dependent protein kinases, which bind to the DNA 
double strand break. Nucleases remove a few bases to form blunt DNA strands that are ligated 
by DNA ligases.  
In contrast to the error-prone repair by NHEJ, homologous recombination (HR) involves 
reactions between three DNA molecules – the two broken DNA ends and the intact DNA 
strand from the sister chromatid. Therefore, HR is normally used during and/or after DNA 
replication, when the sister chromatid is available for use as a template in the repair process. 
The initial step in the repair of DNA double strand breaks by Homologous Recombination is 
the end resection in order to generate 3´overhangs, which is normally done by the MRN 
complex. The 3´-overhangs are coated by the coiled-coils of RAD50 to protect the DNA ends 
from further resection and prevent the formation of secondary structures. Afterwards, RAD51 
binds to the single-stranded DNA ends and searches for the homologous DNA sequence in the 
sister chromatid. RAD51 mediates the strand invasion and the 3´-overhang is elongated by 
DNA polymerase that uses the complementary strand in the undamaged homologous DNA as 
a template. The so-called Holliday junction is processed and resolved by DNA helicases and 
nucleases. Because this repair mechanism uses the undamaged homologous DNA strand as a 
template, HR is an error free way to repair DNA double strand breaks. 
 
3.4.3. Cell Cycle, Cell Cycle Arrest and Apoptosis/Necrosis 
The cell cycle is an ordered series of events a proliferating eukaryotic cell passes through. Two 
processes have to occur in the cell for it: the doubling of the genomic DNA, which is done in 
the S-Phase and the halving of the genome during mitosis (M-Phase). The cell cycle consists of 
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two different stages: the Interphase – starting with the G1-Phase and going through S-Phase 
to the G2-State – and the M-Phase. After cell division each daughter cell can enter a new cycle 
or can leave the cycle and stay in the G0-Phase – a resting stage, which is common for fully 
differentiated cells (e.g., neurons).  
During the G1-Phase the cells synthesize RNAs, proteins and increase in size, before they 
replicate the DNA in the S-Phase. This is followed by a second G-Phase (G2), in which the cells 
continue to grow and synthesize additional proteins. In the subsequent M-Phase the 
eukaryotic cells separate into two similar daughter cells. This phase is sub-divided into four 
stages – prophase, metaphase, anaphase and telophase - finished by cytokinesis. In eukaryotic 
cells, special proteins are involved in controlling the cell cycle – cyclin-dependent-kinase-
complexes. These complexes are composed of a regulatory cyclin subunit and a catalytic 
cyclin-dependent-kinase (CDK) subunit. 
At the transition between the G1/S-phase and the G2/M-Phase and at the end of the S-Phase, 
there are checkpoints that monitor the integrity of the specific cell cycle event before 
progressing into the next phase. UV-light, ionizing radiation, chemicals and other endogenous 
or exogenous agents can cause DNA damage. Before mitosis, DNA damage has to be repaired 
to avoid the transfer of damaged DNA to daughter cells. The G1/S-checkpoint prevents the 
replication of damaged DNA-matrices and the G2/M-checkpoint the segregation of damaged 
chromosomes. The cell cycle checkpoints function as control points to arrest the cell cycle and 
to determine whether the damage can be repaired and the cells progress in cell cycle or cannot 
be repaired and the cells have to undergo apoptosis. To stop the cells at these checkpoints, 
special proteins – checkpoint kinases - are needed to recognize and repair DNA damage as 
well as to control the cell cycle arrest and the way to apoptosis.  
Apoptosis – also called programmed cell death – is the intracellular death program that exactly 
balances cell division, to ensure that only non-damaged cells divide. Another form of cell death 
is called necrosis. During necrosis a cell swells and bursts as a result of acute injury causing a 
potentially damaging inflammation response. During apoptosis, in contrast, the cell shrinks 
and condenses, the cytoskeleton collapses, the nuclear envelope disassembles, and the 
nuclear DNA breaks up into fragments. All cellular compartments are packed into so-called 
“apoptotic bodies”, which are phagocytosed either by a neighbouring cell or a macrophage. 
Leakage of cell content does not occur, thus avoiding the damaging consequences of cell 
necrosis and allowing the recycling of the cellular components by the ingesting cell (Elmore 
2007). 
  
3.5. ATM and Cancer 
A defective DNA damage repair machinery can lead to an accumulation of DNA breaks and/or 
mutations in the DNA. The cell cycle can be disturbed, which can lead to an uncontrolled cell 
division and an increased incidence of cancer.  
  
19 
 
As already described above, A-T patients are at an increased risk of malignancy and are 
estimated to have a 100-fold increased risk of cancer compared to the general population 
(Ahmed und Rahman 2006).  The combination of increased cellular radio-sensitivity, cell cycle 
checkpoint defects and chromosomal instability leads to the development of malign tumors 
in more than 30% of AT patients. Most AT patients are compound heterozygous for truncating 
mutations or carry one truncating mutation and one missense mutation. Homozygous carriers 
are uncommon, except in consanguineous families or in the case of specific founder 
mutations. Before the ATM genes was identified, it was already suggested that the blood 
relatives of A-T patients (obligate or potential heterozygous ATM mutation carriers) have an 
increased risk of cancer, especially breast cancer (Swift et al. 1991). Easton at al. supported 
this by the meta-analysis of several studies and estimated the relative risk for breast cancer in 
AT heterozygotes at 3.9-fold (Easton 1994). But there were also reports that could not find 
any evidence for an increased risk of ATM mutations in breast cancer patients (FitzGerald et 
al. 1997). In 2006, Renwick et al. tried to resolve the confusion regarding the role of ATM 
mutations in breast cancer susceptibility and published the first case-control study in which 
they compared the frequency of ATM mutations in familial breast cancer vs. controls (Renwick 
et al. 2006). AT heterozygotes showed an estimated relative risk for breast cancer of 2.37. 
However, all these studies are inconclusive because of the small number of cases and most of 
them screened only a part of the ATM gene for specific mutations. Nevertheless, together the 
results from Renwick (case-control study) and Thompson (epidemiological study) indicate a 2-
fold risk for breast cancer in AT heterozygotes (Thompson et al. 2005). Only 15% of them will 
develop breast cancer in their life, compared to BRCA1/2, which have a 15-fold risk of breast 
cancer and 70% of them will develop breast cancer. Thus, it seems likely that ATM is associated 
with a moderate risk of breast cancer, but it is still not clear if ATM mutations can act 
multiplicatively and in consideration of the cellular radiosensitivity the ATM mutation status 
might influence the response to radiotherapy (Angèle und Hall 2000; Gutiérrez-Enríquez et al. 
2004; Meyer et al. 2004). Therefore, future research will be crucial to understand the impact 
of ATM mutations on breast cancer, breast cancer therapy and the role of ATM in cell cycle 
control, DNA repair and cellular radiosensitivity.  
 
3.6. Breast cancer  
Breast cancer is one of the most commonly diagnosed cancers. It is the second leading cause 
of cancer death in women. Breast cancer is classified into different types based on histology. 
The ductal carcinoma starts in the lining of the breast milk ducts. The non-invasive or pre-
invasive cancer is called carcinoma in situ and during this stage the cancer cells have not 
spread into the surrounding breast tissue yet. If the cancer cells break through the wall of the 
duct and grows into the fatty tissue of the breast it is called an invasive ductal carcinoma. At 
this point, the cancer cells are also able to metastasize. Another form is the lobular carcinoma 
where the cancer cells originate from the lobules – the milk-producing glands. Like a ductal 
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carcinoma, it is also able to metastasize in the surrounding tissue. Less common types of 
breast cancer are, for example, the inflammatory breast cancer – where cancer cells block the 
lymph vessels of the skin – which looks like an inflammation of the breast skin. Like other 
cancers, breast cancer is staged by the TNM system, which gives codes to describe the severity 
of the cancer. This system is based on the size/extent of the primary tumor (‘T’), the 
involvement of nearby lymph nodes (‘N’), and the distant metastasis (‘M’).  
There are a few known risk factors for breast cancer such as age (due to a reduced capability 
to repair DNA damage), environmental and lifestyle factors (radiation to the chest, combined 
hormone replacement therapy, overweight, nulliparity, late first birth, early menarche and 
late menopause), and genetic factors. A genetic contribution is indicated by the increased 
incidence of breast cancer in women with a family history. In the latter case, multiple relatives 
are affected, they can show an early age of diagnosis, the occurrence of bilateral or multiple 
ipsilateral breast cancer and sometimes affected male relatives. Based on the risk and 
frequency, there are currently three breast cancer susceptibility genes or loci recognized. They 
are classified into high risk genes (BRCA1 and BRCA2), intermediate risk genes (ATM and 
CHEK2), and modest-risk genes or loci. Mutations in the high risk genes confer a 5-10-fold 
increased risk for breast cancer, while for intermediate and low risk loci, respectively, a 2-5-
fold and a 1.25-fold increased risk has been recognized. 
 
3.7. ATM Missense Mutation c.7271T>G  
In this part, I will give an introduction to the missense mutation c.7271T>G of the ATM gene, 
which has been studied quite extensively. In 1998, Stankovic (Stankovic et al. 1998) reported 
the spectrum of different ATM mutations in the British Isles. They described three affected 
members of a family (in the publication this family is referred to as family 109), which showed 
long-standing ataxia. The index patient had severe truncal ataxia, but could still walk with 
support at the age of 48 years; slightly peripheral ataxia; oculomotor apraxia; reduced muscle 
tone and reflexes in arms and legs and progressive dysarthria. She showed only minimal 
telangiectasia – except on the right breast, as a side effect of a postoperative radiotherapy 
after an invasive ductal carcinoma (at the age of 44 years), which was treated with 
lumpectomy and conventional radiotherapy. Four years later, she developed an intraductal 
carcinoma in situ in the contralateral breast, which was treated by lumpectomy only. The 
brother of the index patient showed abnormal head movements since the age of three years 
and ataxia with 9 years. His neurological course was similar to that of his sisters, but slightly 
more severe. The sister of the proband also showed a similar neurological course. Quite 
unusual for A-T patients, she gave birth to a normal son at age 37, with no history of 
miscarriage or stillbirth. Like her sister, she also developed an invasive ductal carcinoma of the 
right breast at the age of 50 years. Interestingly, the mother of the sisters also developed 
breast cancer at the age of 82 years, but that may have been sporadic. Stankovic could detect 
a missense mutation in the ATM gene for this family and a second family (family 46), which 
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was the only change in the ATM gene that was observed in the family 109. Additionally, this 
missense change segregates with A-T and breast cancer in both families and showed a mild 
clinical phenotype with lower a reaction to radiation. This missense mutation was present in 
a homozygous state in all patients of family 109 and together with a second frameshift 
mutation in all patients in family 46. The c.7271T>G transition leads to a change from a highly 
conserved valine to a glycine at position 2424 on the protein level, which changes a large 
hydrophobic amino acid into a small amino acid. Additional analysis showed an increased 
number of chromosomal breaks after irradiation of whole blood samples with 1 Gy compared 
to control cells but not as high as in classical A-T patients. Western Blot analysis revealed a 
full-length ATM protein for the c.7271 homozygous carriers and compared to heterozygous 
c.7271 carriers and normal individuals the same amount of ATM protein. In contrast, patients 
who carry the c.7271T>G missense mutation and the frameshift mutation (members of family 
46) had a reduced level of ATM protein compared to control cells in western blot analysis. 
Stankovic postulated that the detected mutant ATM protein showed residual function and, 
therefore, a ‘dose response’ effect, in which the degree of mildness depended on the level of 
mutant but functional ATM protein. Furthermore, the history of both families showed that 
female heterozygotes were at an increased risk for breast cancer and this observation raised 
the possibility that the cancer risk might be higher for certain ATM mutations. In 1999, Gatti 
(Bernstein et al. 2003; Gatti et al. 1999) picked up these assumptions and also put forward a 
model to explain the apparent contradiction between the epidemiological studies and the 
case-control comparison of ATM in breast cancer. He differentiated between ATM missense 
mutations, which lead to the production of an altered ATM protein, and truncating mutations 
that result in no or less ATM protein. The truncating mutations are less frequent compared to 
the missense variants, predispose to AT and may have some cancer predisposing effects but 
they are not major cancer susceptibility alleles in the general population. In contrast, the 
altered ATM protein resulting from missense mutations can be incorporated into the protein 
complex and may thus disrupt the function of this complex, which could result in additional 
phenotypic effects and the absence or substantial reduction of ATM protein concentration. In 
2002, Chenevix-Trench (Chenevix-Trench et al. 2002) screened multiple-case breast cancer 
families, which were negative for mutations in BRCA1/2, a large number of unselected breast 
cancer patients and controls for two ATM mutations, that reportedly increased the risk for 
breast cancer. One of them was the c.7271T>G transition. The other one was a splice mutation 
that leads to an incorrect splicing of exon 11 and results in an exon skipping and a truncated 
ATM protein. They could find one family, in which the heterozygous missense mutation 
c.7271T>G segregated with breast cancer. They established lymphoblastoid cell lines of all 
mutation carriers for in vivo analysis. After irradiation with 6 Gy, Western Blot analysis 
revealed full length ATM protein for homozygous carriers of c.7271T>G comparable to control 
cell lines and c.7271T>G heterozygous carriers. However, additional Western Blot analysis for 
downstream targets of ATM showed a completely abolished p53 phosphorylation in 
c.7271T>G homozygous carriers. c.7271T>G heterozygous carriers had only 15-25 % of normal 
kinase activity – measured by p53 and BRCA1 phosphorylation - compared to normal controls. 
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Based on these results Chenevix-Trench hypothesized that the c.7271T>G mutation acts in a 
dominant-negative manner and, therefore, the wild-type enzyme is unable to function 
normally in the presence of the altered protein, due to competition effects for binding 
partners, substrates and regulators and, therefore, increases the risk for breast cancer in these 
women. The hypothesis of mutations with a dominant negative effect was first published by 
Herskowitz in 1987 (Herskowitz 1987). Interestingly, while the c.7271T>G variant segregates 
with breast cancer in this family, the affected and unaffected mutation carriers showed a 
reduced kinase activity compared to the control cell lines and heterozygotes were not 
radiosensitive in vitro.  
In 2006, Waddell could identify two additional index cases that carried the c.7271T>G 
variation and tried to characterize this alteration by gene expression profiling (Waddell et al. 
2006). Back in 2002 Watts used gene expression profiling to determine AT carriers and could 
show that mutation carriers show an “expression phenotype” (Watts et al. 2002), which could 
be a new approach to identify carriers. They used microarray analysis to compare expression 
profiles of lymphoblastoid cell lines from AT carriers vs. controls with and without irradiation. 
71 genes were identified and four genes (LIM, CDKN2D, TFRC and ARF6) could be used to 
discriminate between AT carriers and controls. However, they did not propose that the 
expression level of these four genes will allow reliable classification due to small sample size. 
In 2006, Waddell et al. picked up this approach and based on the hypothesis, that the missense 
mutation c.7271T>G acts in a dominant-negative manner, they assumed that c.7271T>G 
carriers would display the same expression and IR sensitive phenotype as truncation mutation 
carriers and, therefore, would confirm the dominant-negative mechanism of the c.7271T>G 
missense mutation. They could identify 77 genes by microarray that were overexpressed in 
heterozygotes and homozygotes c.7271T>G compared to wild-type family members and 
unrelated controls. All these genes are involved in cell growth and cell maintenance, signal 
transduction and nucleic acid metabolism, but they could not identify any of the genes Watts 
et al. had found in their expression study in 2002. Western blot analysis for p53 and 
phosphorylated p53 (Ser15) were carried out to study radiosensitivity. The heterozygous and 
homozygous c.7271T>G carriers showed a wide range of response and interestingly in the 
publication from 2006 Waddell could not confirm the results from 2002 for all cell lines. In 
contrast to the previously reported results, the phosphorylation of p53 at Ser15 was 
comparable between the wild-type cell lines and c.7271T>G heterozygotes. The authors 
justified this discrepancy with the assumption that in the previous study they had used freshly 
established lymphoblastoid cell lines and that the prolonged in vitro culture of the cell lines 
might have compromised the dominant-negative effect. Nevertheless, the heterozygous 
c.7271T>G carriers showed higher levels of p53 and phosphorylated p53, which is consistent 
with most of the reported cultured AT cell lines and might be due to the activation of other 
cellular DNA damage repair pathways after ionizing radiation. The use of other DNA damage 
pathways is supported by the observation that c.7271T>G homozygotes show the highest 
incidence of chromosomal aberrations, followed by heterozygous carriers and, thereafter, 
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wild-type cells. In 2009, Tavtigian et al. picked up the theory of the dominant negative 
mechanism in c.7271T>G carriers. They developed a strategy to estimate the risk attributable 
to rare missense variants on susceptibility genes for breast cancer to improve the power of 
case-control mutation screening studies. Therefore, they screened data of seven published 
ATM case-control studies and could show that rare missense variations – that are in the last 
third of the ATM protein – confer an increased risk of breast cancer. Additionally a subset of 
these missense mutations confer a higher risk for breast cancer than classical AT mutations, 
which resembles the hypothesis of Gatti in 1999 (Bernstein et al. 2003; Gatti et al. 1999). Gatti 
proposed that these ATM variations are common in the general population, whereas Tavtigian 
hypothesizes that the high-risk variations in the FAT-, kinase and FATC-domain of the ATM 
protein are very rare in the population. They also note that relatively common ATM missense 
mutations individually confer a moderately increased risk for breast cancer. Therefore, it is 
very important to complement these bioinformatics and statistical results with functional 
assays to reclassify these missense variations as clearly or likely pathogenic in matters of 
breast cancer susceptibility. 
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3.8. Motivation 
Ataxia Telangiectasia is an autosomal recessive, multisystem disorder characterized by 
progressive cerebellar ataxia, telangiectasia, immune defects and a predisposition to 
malignancy. It has an estimated prevalence of 1:400,000 and a heterozygous frequency of 1% 
in the general population. The gene mutated in this disease was identified on chromosome 
11q22-23 and named Ataxia Telangiectasia Mutated (ATM). To date, more than 350 different 
mutations have been described that are distributed over the entire gene. More than 70% of 
the mutations are truncating mutations that lead to a destabilization of the resulting protein. 
The ATM protein is a 350 kDa serine-threonine protein kinase that localizes mainly to the 
nucleus. It plays a key role in the repair of DNA double strand breaks that are typically induced 
by ionizing radiation, thereby activating ATM. ATM in turn activates many downstream targets 
such as DNA damage repair mechanisms by SMC1 or CHK2 and the p53-pathway leading either 
to cell cycle arrest, the repair of the DNA damage or the induction of apoptosis. Disturbances 
in these mechanisms can result in an accumulation of DNA alterations that predispose the 
damaged cells to malignant transformation.  
Since 1991, ATM has been discussed as a susceptibility gene for breast cancer (Swift et al. 
1991), in particular a missense mutation located in the C-terminal third of the ATM protein 
(c.7271T>G, p.Val2424Gly). For this missense variation a dominant-negative mechanism is 
described in the literature and in 2006 Waddell used expression profiles to discriminate 
c.7271T>G carriers from healthy controls (Chenevix-Trench et al. 2002; Waddell et al. 2006). 
Based on these expression profiles and the assumption of a dominant-negative effect for the 
c.7271T>G substitution, I used proteomics-based approaches to elucidate the cellular 
reactions upon ionizing radiation of lymphoblastoid cell lines from AT patients carrying 
different ATM-mutations, breast cancer patients heterozygous for c.7271T>G, one AT patient 
homozygous for c.7271T>G, and healthy controls. Based on available literature and the 
postulated dominant-negative effect, cell lines harboring the c.7271T>G mutation should 
react in the same manner as cell lines derived from A-T patients with bona fide ATM 
mutations. Further, it should be possible to distinguish carriers of c.7271T>G by noninvasive 
methods like protein assay and/or chromosomal break analysis.  
1. A differential proteomics-approach 2D-gel electrophoresis was used to investigate the 
response of the protein network in the nucleus to ionizing radiation.  
2. A targeted approach was used to identify impaired pathways and check the 
phosphorylation status of ATM and downstream targets.  
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4. Material and Methods  
4.1. Materials 
4.1.1. Chemicals and Kits 
Compound Supplier 
3-[(3-Cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS) 
AppliChem, Darmstadt 
4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES)  
Sigma-Aldrich Chemie GmbH, Munich 
Acetic acid Sigma-Aldrich Chemie GmbH, Munich 
Acetone Sigma-Aldrich Chemie GmbH, Munich 
Amido Black Sigma-Aldrich Chemie GmbH, Munich 
Ammonium acetate Sigma-Aldrich Chemie GmbH, Munich 
Annexin V-FITC Kit  Beckman Coulter, Krefeld 
Bromophenol blue GE Healthcare Europe GmbH, Freiburg 
Colcemid Sigma-Aldrich Chemie GmbH, Munich 
Coulter Clenz  Beckman Coulter, Krefeld 
Dithiothreitol (DTT) Sigma-Aldrich Chemie GmbH, Munich 
Dulbecco´s PBS (1x) without Mg and Ca, sterile PAA, Pasching (Austria) 
Ethylenediaminetetraacetic acid (EDTA) Carl Roth GmbH + Co KG, Karlsruhe 
ELISA Kit for NFĸB (p65) Rockland Immunochemicals Inc.  
Fetal Bovine Serum Gold (FBS) EU-approved  PAA, Pasching (Austria) 
Giemsa Carl Roth GmbH + Co KG, Karlsruhe 
IsoFlow Sheath Fluid  Beckman Coulter, Krefeld 
L-Glutamine, liquid, 200 mM  PAA, Pasching (Austria)  
Magnesium chloride (MgCl2) Sigma-Aldrich Chemie GmbH, Munich 
Methanol VWR International GmbH, Darmstadt 
NP 40 Biochemica UK Ltd, Billingham, UK 
p65 ELISA Kit Rockland Immunochemicals Inc. 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich Chemie GmbH, Munich 
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Phenol Sigma-Aldrich Chemie GmbH, Munich 
Phosphatase Inhibitor Sigma-Aldrich Chemie GmbH, Munich 
Potassium chloride (KCl) Merck KGaA, Darmstadt 
Propidium iodide Fluka, Buchs, Switzerland 
Proteinase Inhibitor Sigma-Aldrich Chemie GmbH, Munich 
RNase A AppliChem GmbH, Darmstadt 
RPMI-1640 without L-glutamine PAA, Pasching (Austria) 
Sodium chloride (NaCl)  Sigma-Aldrich Chemie GmbH, Munich 
Sodium dodecyl sulfate (SDS) Carl Roth GmbH + Co KG, Karlsruhe 
Sucrose Sigma-Aldrich Chemie GmbH, Munich 
Thiourea GE Healthcare Europe GmbH, Freiburg 
Trichloroacetic acid (TCA) Sigma-Aldrich Chemie GmbH, Munich 
Tris(hydroxymethyl)aminomethane (Tris) USB Corporation, Cleveland (USA) 
Tris-HCl Carl Roth GmbH + Co KG, Karlsruhe 
Urea GE Healthcare Europe GmbH, Freiburg 
Table 1: Chemicals and Kits 
 
4.1.2. Buffers 
Name Composition 
Bromophenol blue solution 1% 50 mM Tris 
1% (w/v) Bromphenol blue 
Buffer A 50 mM NH4HCO3 in aqua dest. 
Buffer B 25 mM NH4HCO3 in 50% acetonitrile 
Buffer N 10 mM Tris-HCl, pH 7.4 
150 mM NaCl 
1 mM EDTA 
0.5% (v/v) Triton X-100 
 
Adding fresh before use: 
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0.5 mM DTT 
0.5 mM PMSF 
Proteinase Inhibitor 
Phosphatase Inhibitor 
Coomassie staining solution  34% (v/v) Methanol 
2% (v/v) Phosphoric acid (98%) 
17% (w/v) Ammonium sulfate 
0.066% (w/v) Coomassie G-250 
Dense SDS-Buffer 30% Sucrose 
2% SDS 
0.1 M Tris-HCl, pH 8.0 
5% 2-Mercaptoethanol 
Equilibration Buffer 50 mM Tris-HCl, pH 8.8 
30% Glycerol (99.9%) 
6 M Urea 
0.002% (w/v) Bromophenol blue 
2% SDS 
Fixation Buffer Methanol : Acetic acid 3:1 
Hypotonic Buffer N  10 mM HEPES, pH 7.5 
2 mM MgCl2 
25 mM KCl 
Adding fresh before use: 
1 mM DTT 
1 mM PMSF 
Proteinase Inhibitor Cocktail 
Phosphatase Inhibitor Cocktail 
L-Buffer  7 M Urea 
2 M Thiourea 
2% (w/v) CHAPS 
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30 mM Tris 
Nuclear Extraction Buffer A 10 mM HEPES, pH 7.6 
15 mM KCl 
2 mM MgCl2 
0.1 mM EDTA 
 
Adding fresh before use: 
1 mM DTT 
0.5 mM PMSF 
Proteinase Inhibitor Cocktail 
Phosphatase Inhibitor Cocktail 
Nuclear Extraction Buffer B Mixing fresh before use: 
Buffer A + 0.2% NP 40  
Nuclear Extraction Sucrose Buffer Mixing fresh before use: 
Buffer A + 0.25 M Sucrose 
Rehydration Buffer  7 M Urea 
2 M Thiourea 
2% CHAPS 
50 µl Bromphenol blue solution 1% 
Solution A  70% Acetic acid 
Solution B  Methanol: Acetic acid 8:1  
Solvent A 0.1% Formic acid 
Solvent B  0.1% Formic acid in acetonitrile 
TBS-T (10x) 100 mM Tris 
150 mM NaCl 
0.5% Tween20  
Table 2: Buffers 
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4.1.3. Antibodies 
 
 
 
 
 
 
 
  
Antigen Company Catalog No Host Dilution  
ATM  Santa Cruz Biotechnology, Inc. Sc-53173 Mouse 1:500 
ATM Acris Antibodies GmbH SP1131 Rabbit  1:1,000 
Calreticulin Calbiochem® 208912 Mouse 1:5,000 
Cytochrom C  Santa Cruz Biotechnology, Inc. sc-7159 Rabbit 1:300 
GADD45A Abcam®  Ab76664 Rabbit 1:1,000 
IKKγ Abcam®  ab13917 Mouse 1:500 
Lamin A  Santa Cruz Biotechnology, Inc. sc-20680 Rabbit 1:1,000 
Mre11 Cell Signaling Technology®  #4895 Rabbit 1:1,000 
p53 Santa Cruz Biotechnology, Inc. sc-126 Mouse 1:500 
p21 Abcam® ab16767 Mouse 1:1,000 
PGK1/2 Santa Cruz Biotechnology, Inc. sc-48342 Mouse 1:5,000 
phospho-ATM (S1981) Santa Cruz Biotechnology, Inc. sc-47739 Mouse 1:500 
phospho-ATM (S1981) Abcam®  ab81292 Rabbit 1:1,000 
phospho-CREB (S121) Novus Biologicals® NB100-410 Rabbit 1:1,000 
phosphor-H2AX (S139) Acris Antibodies GmbH AP20846PU-N Rabbit 1:1,000 
phospho-IKKγ (Ser85) Abcam® ab63551 Rabbit 1:500 
phospho-NBS1 (S343) Acris Antibodies GmbH AP02356PU-N Rabbit 1:1,000 
phospho-p53 (Ser15)  Santa Cruz Biotechnology, Inc. sc-101762 Rabbit 1:1,000 
phospho-SMC1 (S966) Bethyl Laboratories Inc. A300-050A Rabbit 1:1,000 
phospho-(Ser/Thr) 
ATM/ATR Substrate 
Cell Signaling Technology®  #2851 Rabbit 1:2,500 
Rad23B ProteinTech 12121-1-AP Rabbit 1:1,000 
SMC1 Bethyl Laboratories. Inc A300-055A Rabbit 1:1,000 
Table 3: Antibodies 
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4.1.4. Euipment and Consumables 
Device Supplier 
Autoklav Systec VX-55 Systec, Wettenberg, Germany 
Bandelin Sonorex® ultrasonic bath Bandelin electronic GmbH & Co KG, Berlin, 
Germany 
BD FACSCaliburTM  BD Biosciences, Singapore 
CASY®TT Cell Counter + Analyzer Roche 
Cellstar® Cell culture flasks  Greiner Bio-One, Frickenhausen, Germany  
Concentrator 5301 Eppendorf, Hamburg, Germany 
Coulter® Epics® XL-MCL  Beckmann Coulter, Krefeld, Germany 
EttanTMDalt six Large Vertical System GE Healthcare Europe, Munich, Germany 
EttanTMIPGphorTM3 IEF System GE Healthcare Europe, Munich, Germany 
Glass slides  
Heraeus® HERAcell 240 CO2 Incubator Thermo Fisher Scientific, Schwerte, Germany 
Heraeus® HERAsafe HS Thermo Fisher Scientific, Schwerte, Germany 
IBL-437 C  Compagnie ORIS Industrie, Gif s/Yvette, 
 France 
QStar XL MS/MS System Applied Biosystems, Darmstadt, Germany 
TripleTOF 5600+ QTOF-mass spectrometer Sciex, Framingham (USA) 
VersaDoc MP4000 BioRad, Hercules, CA, USA 
Wilovert S inverse Microscopy  Helmut Hund, Wetzlar, Germany 
Table 4: Equipment and Consumables 
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4.1.5. Software 
 
Program Supplier 
Coulter Expo 32 Beckman Coulter 
Image Lab BioRad, Hercules, CA, USA 
Mascot 2.2 Matrixscience, London (UK) 
MultiCycle AV for Windows Phoenix Flow Systems 
PeakView 2.2 Sciex, Framingham (USA) 
Progenesis Same Spots Nonlinear Dynamics 
Protein Pilot 4.5 Sciex, Framingham (USA) 
Quantity One  BioRad, Hercules, CA, USA 
Analyst 1.7TF Sciex, Framingham (USA) 
Table 5: Software 
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4.2. Cell Culture 
4.2.1. Cell lines 
EBV-transfected lymphoblastoid cell lines were obtained from Coriell Cell Repositories (CCR) 
at the Coriell Institute for Medical Research, Camden, NJ, USA (CEPH French Pedigree and 
Ataxia Telangiectasia Patients) and from the Kathleen Cuningham Foundation Consortium for 
Research into Familial Breast Cancer, (kConFab) (Breast Cancer Patients with 7271T>G 
mutation).  
Name Description 
GM12548 Caucasian; CEPH French Pedigree 
GM12561 Caucasian; CEPH French Pedigree 
GM12672 Caucasian; CEPH French Pedigree 
GM12699 Caucasian; CEPH French Pedigree 
GM08436 Caucasian; Ataxia Telangiectasia 
Paternal allele: 4642delGATA; D1548fsX 
Maternal allele: 5932G>T; skipping Ex42; E1978X 
GM09587 Caucasian, Ataxia Telangiectasia 
Paternal allele: 9022C>T; 735C>T 
Maternal allele: 4bp-del IVS59+1 
GM13762 Caucasian, Ataxia Telangiectasia 
Paternal allele: 8565TG>AA 
Maternal allele: 6997insA; truncated protein 
GM13805 Caucasian, Ataxia Telangiectasia 
Paternal allele: 6736del20ins2; protein truncation 
Maternal allele: 1229T>C 
98.004.0011 Caucasian, Breast Cancer Patient  
(Heterozygous: 7271T>G)  
98.004.0012 Caucasian, Breast Cancer Patient  
(Heterozygous: 7271T>G)  
98.004.0034 Caucasian, Breast Cancer Patient  
(Heterozygous: 7271T>G)  
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03.005.1294 Caucasian, Breast Cancer Patient  
(Heterozygous: 7271T>G)  
109 II-6  Caucasian, Ataxia Telangiectasia 
(Homozygous: 7271T>G)  
Table 6: Cell lines used in this study 
 
4.2.2. Cell Culture Conditions and Irradiation Treatment 
All cell lines were cultured with RPMI1640 containing 15% non-heat inactivated fetal bovine 
serum and 2 mM L-glutamine in a humidified incubator at 37°C in 5% CO2 in culture flasks 
(25cm2 or 75 cm2) with filter cap. Media was changed 24 hours before treatment and cells 
were seeded at a final concentration of 1.5 x 106 cells/mL. All cell lines were irradiated with 3 
Gy or mock-irradiated using an IBL-437 C (Cesium-137 gamma radiation) blood irradiator and 
incubated afterwards for 6 hours in the incubator.  
 
4.3. Flow Cytometry 
4.3.1. Annexin-PI-Staining 
Flow cytometry was done to check the viability of the cells after irradiation/mock-irradiation. 
Therefore, the annexin V – propidium iodide staining kit from Beckmann Coulter was used 
according to the manufacturer´s protocol. 
After treatment and incubation, 2 x 106 cells were collected and centrifuged at 150 x g for 8 
min at 8°C. The resulting pellet was resuspended in 100 µL of 1x binding buffer and 1 µL of 
annexin-FITC and 5 µL of propidium iodide staining solution were added. After incubation for 
15 min on ice, 400 µL of 1x binding buffer were added and samples were measured 
immediately on a Coulter® Epics® XL-MCL Expo 32.  
For subsequent sample preparation only cell cultures with a viability ≥ 90% were used. 
 
4.3.2. Propidium Iodide (PI)-Staining 
The PI-staining for cell cycle analysis was done in cooperation with Dr. Michael Gruber 
(Department of Anesthesiology, University Hospital Regensburg, Regensburg, Germany).  
For cell cycle analysis, 1 x 106 cells were washed twice with ice-cold PBS/5 mM EDTA and 
centrifuged at 2,000 x g for 5 min at 4 °C, followed by a fixation step with 100% ethanol and 
an incubation time of 30 min at room temperature. After centrifugation at 2,000 x g for 5 min 
at 4 °C, 20 µL of RNase A were added and the suspension was incubated at room temperature 
for 30 min. Finally, staining with 5 µL propidium iodide (100 µg/mL) was carried out followed 
by sample analysis on a BD FACSCaliburTM.  
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4.4. Chromosomal Break Analysis  
Chromosomal break analysis was done in cooperation with the Center of Human Genetics 
(Praxis und Labor für Humangenetik Hehr, Regensburg, Germany; Prof. Dr. U. Hehr).  
After irradiation/mock-irradiation, colcemid was added to the cells (final concentration 10 
µg/ml) incubated for 30 min at 37 °C in 5% CO2. Afterwards, cells were centrifuged at 150 x g 
at 8°C for 8 min, resuspended in 0.4% pre-warmed KCl and incubated for 10 min at room 
temperature. Next, the cells were resuspended and washed three times with ice cold Fixation 
Buffer (methanol: acetic acid 3:1) and finally stored at -20 °C.  
To separate metaphases, the suspensions were dropped on ice cold glass slides, dried at 50 °C 
overnight and stained with Giemsa. The metaphases were captured and chromosomal breaks 
were counted.  
 
4.5. Enzyme-Linked Immunosorbent Assay (ELISA)  
To determine the activity of NFĸB (p65) in nuclear lysates of irradiated and mock-irradiated 
cells 6 hours after irradiation, an ELISA Kit (Rockland Immunochemicals Inc.) was used 
according to the manufacturer’s protocol.  
A plate - coated with the ds-DNA sequence containing the NF-ĸB response element - was 
incubated at 4 °C overnight with 10 µg of nuclear lysate. After washing, the plate was 
incubated with the first antibody for one hour at room temperature and after an additional 
washing step the secondary antibody was applied. After a third washing step a developing 
reagent was added and the absorbance was measured at 450 nm by a photometer.  
 
4.6. Nuclei Extraction  
After irradiation and incubation, 108 cells were harvested, centrifuged at 150 x g and 8 min at 
8 °C and washed three times with ice-cold PBS. For nuclei extraction, all steps were carried 
out on ice.  
4.6.1. Nuclei Extraction adapted from Collas et al., 1998 (Collas P.) 
The cell pellets were resuspended in 10 volumes of ice-cold hypotonic buffer N and 
transferred to a 2.0-mL reaction tube. The cells were chilled on ice for 30 min and 
homogenized with a glass Dounce pestle. After cell lysis, 125 µL of 2 M sucrose solution per 
mL cell lysate were added and mixed by inversion. After centrifugation at 150 x g and 8 °C for 
8 min and an additional washing step with ice-cold hypotonic buffer N, the supernatant 
(cytosolic fraction) as well as the pellet (nuclear fraction) were stored a -80 °C.  
  
35 
 
4.6.2. Nuclei Extraction adapted from Hoppe-Seyler et al., 1991 (Hoppe-Seyler et 
al. 1991) 
The pellet was resuspended in 750 µL of buffer N, transferred to a 2.0-mL reaction tube and 
left on ice for 5 min. After centrifugation at 1,250 x g and 8 °C for 5 min the supernatant 
(cytosolic fraction) and the pellet (nuclear fraction) were stored at -80 °C. 
4.6.3. Nuclei Extraction adapted from Rascle et al., 2003 (Rascle et al. 2003) 
After washing with PBS, the cell pellet was resuspended in 1 mL buffer A and transferred to a 
2.0-mL reaction tube. The cells were centrifuged at 850 x g and 4 °C for 1 min and gently 
resuspended in 1.2 mL buffer B. After centrifugation at 350 x g and 4 °C for 1 min the 
supernatant (cytosolic fraction) was kept and the pellet (nuclear fraction) was washed with 
0.5 mL sucrose buffer, centrifuged and washed again with 0.5 mL buffer A. Afterwards, the 
nuclear and cytosolic fractions were stored at -80 °C.  
 
4.7. Protein Precipitation  
After sample preparation the proteins of the cytosolic fraction were precipitated with 100% 
ice-cold ethanol at -20 °C overnight. Afterwards the pellet was air dried and dissolved in L-
buffer.  
The proteins of the nuclear fraction were precipitated according to the protocol of Wang et 
al., 2003 (Wang et al. 2003). First, the pellet was resuspended in 10% TCA/acetone and 
centrifuged at 14,000 x g and 4 °C for 3 min. This was followed by a first washing step with ice-
cold 80% methanol / 0.1 M ammonium acetate and a second washing step with 80% ice-cold 
acetone. Afterwards, the proteins were extracted using a 1:1 mixture of phenol and dense 
SDS-buffer, pH 8.0. This mixture was centrifuged at 16,000 x g and 4 °C for 3 min to separate 
the two phases. The upper phenol phase was transferred in a new 2.0-mL reaction tube, mixed 
with 5 volumes of ice-cold 80% methanol / 0.1 M ammonium acetate and stored at -20 °C 
overnight. After centrifugation at 16,000 x g and 4 °C for 3 min the pellet was washed first 
with 100% ice-cold methanol and in a second step with 80% ice-cold acetone. Afterwards, the 
pellet was air dried and dissolved in L-buffer.  
 
4.8. Protein Quantification 
After protein precipitation the protein content of the cytosolic fraction was determined using 
the FluoroProfile® Kit according to the manufacturer’s protocol.   
For the protein quantification of the nuclear fraction a modified protocol from Schaffner and 
Weissmann, 1973 (Schaffner and Weissmann 1973) was used. The sample was diluted 1:100 
with Aqua dest. and 200 µL of solution A were added. After incubation on ice for 10 min the 
sample was centrifuged at 4,000 x g and 4 °C for 5 min and washed three times with solution 
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B. Finally, the precipitate was dissolved in 400 µL 1 M NaOH and the absorption was measured 
with a photometer at 595 nm. To quantify the sample, a BSA standard (0.3 µg to 20 µg) was 
used.  
 
4.9. Immunoblotting  
For gel electrophoresis, the nuclear samples were denatured at 96 °C for 10 min. Five µg of 
protein per lane were loaded on a pre-cast polyacrylamide gel that was run according to the 
manufacturer’s protocol.  
To separate proteins with a molecular weight > 150 kDa, the NuPAGE® 3-8% Tris acetate pre-
cast polyacrylamide gel system was used. For proteins with a molecular weight between 25 – 
150 kDa, the NuPAGE® 4-12% Bis-Tris pre-cast polyacrylamide gel system, and for proteins < 
25 kDa Novex® 16% tricine gels were used. After separation, the proteins were blotted on a 
PVDF membrane (Immobilon-P or Immobilon-PSQ for proteins < 25 kDa). The protein transfer 
was carried out in an XCell SureLock® Blot Module with 25 V at 4 °C according to the 
manufacturer’s protocol.  
To transfer proteins with a molecular weight >150 kDa and < 25 kDa the following transfer 
buffers were used:  
800 mL  Aqua dest 
150 mL  Methanol 
50 mL 20 x NuPAGE ®Transfer buffer  
Table 7: Transfer Buffer 1 
 
For proteins with a molecular weight range from 25 – 150 kDa the following transfer buffer 
was used: 
850 mL  Aqua dest 
100 mL  Methanol 
50 mL 20 x NuPAGE ®Transfer buffer  
Table 8: Transfer Buffer 2 
 
The successful protein transfer was controlled by Ponceau red staining and afterwards the 
membrane was incubated with Roti®Block at 4 °C overnight. The PVDF membrane was washed 
three times with 1 x TBS-T and incubated with the first antibody (diluted in 1x TBS-T). The 
required concentration was checked before with a test experiment. After three additional 
washing steps the second antibody was applied diluted in 1x TBS-T. This was followed by three 
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subsequent washing steps with 1 x TBS-T and afterwards the immunopositive bands were 
visualized by using Amersham ECL PlusTM Western Blotting Detection Reagent as directed by 
the manufacturer. Equal protein loading was monitored by staining an identically loaded gel 
with Coomassie Brillant Blue.  
 
4.10. 2D-Gel Electrophoresis 
4.10.1. Isoelectric Focusing (1st Dimension)  
For the analysis of the nuclear proteome of the irradiated and non-irradiated cells, two 
different pH gradients were used. 
The nuclear samples were separated either on ImmobilineTM DryStrips Gels pH 3 – 10 
(nonlinear), 24 cm, or on SERVA IPG BlueStrips pH 3 - 10; 24 cm. In contrast, the cytosolic 
proteins were run on SERVA IPG BlueStrips pH 4 - 7; 24 cm.  
The strips were rehydrated overnight with rehydration buffer and the samples were applied 
via cup-loading at the acidic end of the IPG strip. Isoelectric focusing was carried out in an 
EttanTM IPGphorTM 3 IEF System with the following settings.  
 
Step and Voltage method Voltage (V) Time (h:min) Vhrs 
Step´n´Hold 150 2:00 300 
Step´n´Hold 300 2:00 600 
Gradient 500 2:00 800 
Gradient 1000 4:00 2250 
Gradient 4000 3:00 7500 
Gradient  6000 0:30 2500 
Step´n´Hold 6000 6:30 39000 
  ∑ 19:00 ∑ ~53000 
Table 9: IEF settings 
 
After the IEF, the strips were equilibrated for 20 min in equilibration buffer supplemented 
with 1% (w/v) DTT for reduction of cystine. In a second equilibration step, the strips were 
incubated for 20 min with equilibration buffer containing 2.5% (w/v) iodoacetamide for 
alkylation of SH-groups.  
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4.10.2. SDS-Polyacrylamide Gel Electrophoresis (2nd Dimension) 
For the second dimension either vertical or horizontal electrophoresis was used.  
Vertical 2nd Dimension 
After the first dimension the IPG strips were sealed with 0.5% agarose in SDS running buffer 
on top of 12.5% acrylamide gels. The SDS-PAGE step was performed on an Ettan™ Dalt six 
Large Vertical System at 5 W per gel for 0.5 h followed by a 4.5 h step with 20 W per gel.  
Horizontal 2nd Dimension 
The IPG strips were applied on a 2D HPETM Large Gel NF 12.5% and run on a HPETM Tower 
System at 1 W per gel. After 30 min, the strip was removed and the second electrophoresis 
was continued at 30 W per gel for 3.5 h.  
 
4.11. In-Gel-Protein Detection 
4.11.1. Pre-Staining with CHROMIS 3x DGE – Minimal Labeling Kit (for the nuclear 
proteome 6 hours after irradiation) 
To study the differences between the irradiated and non-irradiated nuclear proteomes the 
samples were labeled with fluorescent CHROMIS Dyes (Cyanagen).  
Briefly, 50 µg each of nuclear extract from the irradiated and non-irradiated cells and a mixture 
of 25 µg from each as internal standard were labeled with different fluorescent dyes according 
to the manufacturer’s protocol. The three samples were combined and loaded via cup loading 
on an IPG strip. After 2D electrophoresis, the spots on the gels were visualized by the FLA-
5000 Imaging system and analyzed using the Progenesis SameSpots software. 
4.11.2. LavaPurpleTM (for the nuclear proteome 1 hour after irradiation and for the 
cytosolic proteome 6 hours after irradiation)  
To compare the nuclear proteome 1 hour after treatment as well as the cytosolic proteome 6 
hours after treatment, the LavaPurpleTM fluorescent staining kit was used. The irradiated and 
non-irradiated samples were run in a single experiment on separate 2D gels, which were 
stained according to the manufacturer’s protocol. Afterwards, the spots on the gels were 
visualized using the VersaDoc™ MP4000 Imaging System and analyzed with the Progenesis 
SameSpots software.  
4.11.3. Coomassie G-250 according to Neuhoff et al., 1988 (Neuhoff et al. 1988) 
Coomassie G-250 staining was used for protein visualization and subsequent spot picking. 
Therefore, the gels were incubated overnight at 4 °C in the Coomassie staining solution. The 
gels were destained the next day with Aqua dest. to remove background staining and 
visualized using the VersaDoc™ MP4000 Imaging System.  
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4.11.4. Silver Staining according to Blum et. al., 1987 (Blum et al. 1987) 
For mass spectrometry-based identification of protein spots, the gels were post-stained with 
a modified silver staining protocol from Blum et al., 1987 (Blum et al. 1987).  
 
4.11.5. Image Analysis 
After separation in the second dimension, gels were visualized using the VersaDocTM MP 
4000 Imaging System or the FLA 5000 Imaging System. Afterwards, the images were cropped 
and imported into the Progenesis SameSpots Software as linear tif-files. First a quality control 
was done, followed by an image alignment and automatic analysis with background 
subtraction and normalization. To compare the gels with each other, a ‘within-subject design’ 
was used and an ANOVA was carried out. Only spots with a p-value ≤ 0.05 and a Power ≥ 0.8 
were used for spot picking.  
 
4.12. Protein Identification with Mass Spectrometry 
4.12.1. In-Gel-Digestion using Trypsin 
After separation in the first and second dimension the gels were analyzed using the Progenesis 
SameSpots software. Gels chosen for picking were stained with silver staining or Coomassie 
G250 and the selected spots of interest were excised. Afterwards the 2D-Spots were washed 
in an alternated way for 10 min in buffer A and 10 min in buffer B. After washing the spots 
Task Chemicals Duration 
Fixation  40% (v/v) Ethanol 
10% (v/v) Acetic acid  
Overnight at 4°C 
Washing 30% (v/v) Ethanol 2 x 20 min  
Washing Water  1 x 20 min 
Sensitizing 0.02% (w/v) Sodium thiosulfate 1 min 
Washing Water 3 x 20 sec 
Staining 0.1% (w/v) Silver nitrate 20 min at 4°C 
Washing Water 3 x 20 min 
Developing 3% (w/v) Sodium carbonate 
0.05% (v/v) Formaldehyde 
Developing time depends on the 
intensity of the spots 
Stop 0.05 M (w/v) EDTA 20 min 
Table 10: Silver staining protocol 
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were dried in a vacuum centrifuge, then digested with trypsin (12.5 ng/µL) overnight at 37 °C 
and extracted using 5% formic acid.  
4.12.2. Nano-LC-MS/MS 
For pre-column concentration, 15 µL of the protein digests were applied by sandwich injection 
onto an Acclaim PepMap 300 C18 pre-column (end-capped, 5 mm x 0.3 mm ID, 3 µm particle 
size, 300 Å pore size, flow rate 10 µL/min) using solvent A operated on a nano-HPLC (Ultimate 
3000, Dionex). Afterwards, the peptides were separated by reversed phase liquid 
chromatography (Acclaim PepMap100 C18; end-capped, 150 mm x 75 µm ID, 3 µm particle 
size, 100 Å pore size) with a 36-min binary gradient from 4 – 40 % solvent B and a flow rate of 
300 nL/min. The nano-HPLC was directly coupled to a QStar XL qTOF mass spectrometer 
equipped with a nano-ESI source. Repeated full scan MS spectra (from m/z 400 – 1.200) were 
acquired for 1 s, followed by two MS/MS scans of the two most intensive precursor ions for 
2.5 s. Every ion selected for fragmentation was excluded for 30 s by dynamic exclusion and 
the trigger threshold was set to 20 counts.  
4.12.3. Data Analysis using Mascot 
All acquired spectra were processed using Mascot 2.2 and database searches were performed 
against the SwissProt human database (last modified 05.2011). Carbamidomethylation, Gln-
pyroGlu (N-term Q) modification and Oxidation (M) were selected as fixed modifications. A 
peptide tolerance of ± 0.2 Da and MS/MS tolerance of ± 0.2 Da were allowed and the number 
of maximum missed cleavages was set to 1. Proteins that were identified by at least 2 unique 
peptides were taken into account and if more than one protein per spot was identified, the 
exponentially modified protein abundance index (emPAI) was consulted for decision.  
4.12.4. SWATH-MS-based analysis of nuclear extracts 
Hundred µg of uclear protein lysate were used for filter-aided sample preparation (Wisniewski 
et al. 2009) and aliquots of 1 µg were used for acquisition of the SWATH-MS runs (Gillet et al. 
2012). For generation of the protein library, six runs were performed using 1 µg. For each run 
one group (controls with/without irradiation; breast cancer patients with/without irradiation 
and A-T patients (including 109II-6) with/without irradiation) were pooled, respectively.  The 
information-dependent acquisition (IDA)-runs for library generation were accomplished on a 
TripleTOF 5600+ mass spectrometer (ABSciex, Darmstadt, Germany) coupled online to a 
Dionex Ultimate3000 nano-HPLC (ThermoFisher, Dreieich, Germany). Nano-HPLC analysis was 
conducted using peptide trapping (Acclaim PepMap, 2 cm length x 200 µm I.D., 3 µm particle 
size, flow rate 5 µL/min, 0.1% formic acid at 35 °C) and a 88-min binary gradient (4-30% B in 
73 min, 30-45% B in 15 min) on a 25 cm Acclaim PepMap column (75 µm I.D., 3 µm particle 
size, flow rate 250 nL/min at 35 °C). The mass spectrometer was operated in IDA-mode with a 
TOF-MS from 400-1000 m/z for 250 ms followed by MS/MS-spectra from 230-1500 m/z of the 
30 most intensive precursor ions for 100 ms per precursor. The data was searched using 
ProteinPilot 4.5 (ABSciex) against the Uniprot-database with the following adjustments: 
sample type “Identification”, Cys alkylation “Iodoacetamide”, digestion “Trypsin”, taxonomy 
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“Homo sapiens”, search effort “RapidID”, detected protein threshold “0.05 (10%)” with false 
discovery rate (FDR) analysis. The result file was used for generation of the libraries of 1,700 
proteins identified with an FDR of 1% by PeakView 2.1 (ABSciex) using only spectra with a 
confidence of 95% or higher of unique, unmodified peptides with up to 6 peptides per protein 
and 6 transitions per peptide. 
Nano-HPLC separation for the SWATH-MS analyses was accomplished using the same 
conditions as in the IDA-run. The typical obtained peak width (base-to-base) was about 30 
seconds. Therefore, the TripleTOF 5600+ was operated in SWATH-mode with a fixed duty cycle 
length of 3.3 s to obtain nine data points per LC peak. After a 50 ms TOF-MS scan, the entire 
m/z range of 400-1,000 was covered using 43 SWATH-windows of a quadrupole isolation 
width of 15 m/z, respectively (Simbürger et al. 2016). For all SWATH-analyses the retention 
times were aligned to the respective library using manually chosen peptides distributed evenly 
over the chromatographic run. For SWATH-processing, XICs were obtained with an “XIC-
width” of 75 ppm and retention time windows of 10 min, respectively. The FDR-threshold was 
set to 1%. 
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5. Results 
5.1. Sequencing breast cancer patients 
In 2002, Chenevix-Trench et al. identified the c.7271T>G variant by an indirect approach using 
the restriction endonuclease assay, followed by direct Sanger sequencing (Chenevix-Trench et 
al. 2002). To verify the substitution conventional Sanger sequencing was applied to all 
lymphoblastoid cell lines of the breast cancer patients. All of them carried the original 
described missense mutation at position c.7271, which leads to an amino acid change at 
position 2424 from valine to glycine (Figure 1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2. Effect of different ATM mutations on cell growth, cell viability 
and cell death after irradiation with 3 Gy 
The irradiation of cells with ionizing radiation leads to DNA damage and subsequent cell cycle 
arrest for DNA repair. In cell culture, lymphoblastoid cell lines double nearly every 36 hours. 
Hence, cell count is an easy and fast measure to assess the effect of ionizing radiation on 
different cell lines. To that end, cells were irradiated with 3 Gy or mock-irradiated, followed 
by a resting step in the incubator. 42 hours after irradiation, the cell number was measured 
using a CASY® cell counter (OMNI Life Science).  Figure 2 displays cell counts (Mio cells per mL) 
for the control cell lines, the cell lines derived from the A-T patients, and the breast cancer 
patients harboring the c.7271T>G variant, respectively. All irradiated cell lines showed a 
decreased number of cells, which could be due to cell cycle arrest and/or an increase in 
apoptotic or necrotic cells.  
7271 BC (1) 
7271 BC (2) 
7271 BC (3) 
7271 BC (4) 
c.7271T>G 
Figure 1: Sequencing results of the 7271 BC patients; the mutant position 
is indicated by the arrow; the normal DNA sequence is shown in the upper 
orange line  
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Figure 2: Cell count for each group (four cell lines per group) measured 42 hrs after irradiation with a CASY cell 
counter (* p≤0.05, unpaired two-tailed student´s Ttest). 
 
To further investigate these groups and to differentiate between late apoptotic/necrotic and 
early apoptotic cells, Annexin-PI staining was carried out, followed by flow cytometry. Flow 
cytometry was developed in 1968 by W. Göhde from the University of Münster and is used to 
measure multiple characteristics of individual particles flowing in single file in a stream of fluid 
(Dittrich und Ghode). Light scattering at different angels can distinguish differences in size and 
internal complexity. Furthermore, cell components can be labelled with fluorescent dyes to 
identify a wide range of cell surface or cytoplasmic antigens.  
To distinguish viable, apoptotic and necrotic cells after irradiation with 3 Gy vs mock-
irradiation, an Annexin-PI staining was carried out. All cell lines were irradiated or mock- 
irradiated followed by a resting step for 42 hours in the incubator and thereafter labelled with 
annexin and PI and measured by flow cytometry. Annexin-PI is used widely to determine if 
cells are viable, apoptotic or necrotic through differences in plasma membrane integrity and 
permeability (Vermes et al. 1995; Vermes et al. 2000). The ability of PI to enter a cell is 
dependent upon the permeability of the plasma membrane. Viable or early apoptotic cells 
have an intact plasma membrane and, therefore, PI cannot enter the cell. Nevertheless, early 
apoptotic cells can be distinguished from viable cells by annexin staining of phosphatidyl 
residues on the cell membrane. In viable cells, these residues position on the inside of the 
plasma membrane, whereas in early apoptotic cells these residues are exposed on the outer 
surface and, therefore, are accessible to fluorescent labelling with annexin.  In late apoptotic 
or necrotic cells the integrity of the cell membrane as well as the nuclear membrane 
decreases, PI can pass through the membranes and intercalate with the DNA. Due to the 
presence of phosphatidyl residues in these necrotic/late apoptotic cells, these cells are double 
positive for PI and annexin. Figure 3 shows the percentage of viable, late apoptotic/necrotic 
and early apoptotic cells after irradiation or mock-irradiation for four cell lines in each group. 
Comparing the viable cells in the three groups without irradiation the percentage is nearly the 
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Fig 1: Viable cells 42 hrs after irradiation 
same in control cells and in cell lines from breast cancer patients harbouring the heterozygous 
c.7271T>G mutation (95.09% (controls) and 94.13% (7271)) and slightly decreased in the A-T 
cell lines (91.13%). However, the amount of early apoptotic cells is much higher in the cells 
derived from A-T patients compared to the control cell lines and the breast cancer cell lines 
(4.49% (controls), 4.84% (7271) and 7.2% (A-T)). The late apoptotic/necrotic show a nearly 
similar trend (0.42% (controls), 1.04% (7271) and 1.67% (A-T)). An irradiation with 3 Gy 
amplified these effects and lead to an increase from 3.6% in the control cell lines vs 11.56% 
and 4.27% in the A-T and breast cancer cell lines. In contrast to this the amount of apoptotic 
cells between the control cell lines and the A-T and breast cancer cell lines, respectively, after 
irradiation decreased from 7.93% in the controls to 5% and 5.39% in the A-T and c.7271T>G 
cell lines, respectively.  
 
Figure 3: Percentage of viable, necrotic and apoptotic cells 42 hours after irradiation with 3 Gy measured by 
A-PI staining using flow cytometry (four cell lines per group) 
 
5.3. Effect of different ATM mutations on cell cycle checkpoints after 
irradiation with 3 Gy 
Irradiation of viable cells with ionizing radiation induces DNA double-strand breaks (DSBs). 
Generally, cells are able to recognize these breaks before they progress to the next phase of 
the cell cycle at so-called cell cycle checkpoints. Control mechanisms at these checkpoints 
ensure that the DNA is intact and that each stage of the cell cycle is completed before the 
following stage is initiated. If damaged DNA is recognized, the progression through the cell 
cycle is blocked until the damage is repaired (= cell cycle arrest). Arrest in G1 and S phase 
prevents copying of damaged bases, which would fix mutations in the genome. An arrest in 
G2 phase allows the repair of damaged DNA. A PI staining followed by flow cytometry reveals 
the percentage of cells at each cell cycle stage.  
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After irradiation with 3 Gy or mock-irradiation, all cells were stained with PI and the 
percentage of cells in each cell cycle phase was measured by means of a flow cytometer. 
Figure 4 shows a significant difference (p = 0.008) in the percentage of cells in the G1 Phase 
between irradiated (33%) and non-irradiated A-T cells (43%), respectively. In contrast, ionizing 
radiation exerted no impact on the relative numbers of control and c.7271G>T breast cancer 
cells in the G1 phase. Comparing the effect of irradiation among all three cell lines, a significant 
difference is shown for the A-T cells compared to the control cells (p = 0.013) and the breast 
cancer cells (p = 0.43*10-4).  
 
Figure 4: Percentage of cells arrested in G1 phase after irradiation with 3 Gy (four cell lines per group) (*p≤0.05, 
(one-way ANOVA with subsequent Tukey´s post hoc T-test)) 
 
In Figure 5 the effect of irradiation in the S phase is depicted. Actually, there is no difference 
between control cell lines, A-T cell lines and cell lines derived from breast cancer patients with 
the c.7271T>G variant with or without irradiation. Nevertheless, an intra-group comparison 
shows a significant difference between irradiation and non-irradiation in the controls and in 
the cell lines derived from A-T patients. The cell lines derived from breast cancer patients that 
harbour the heterozygous c.7271T>G variant show the same trend but a higher variance.  
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Figure 5: Percentage of cells arrested in S phase after irradiation with 3 Gy (four cell lines per group) (*p≤0.05) 
(one-way ANOVA with subsequent Tukey´s post hoc T-test)) 
 
The percentages of cells in the G2-/M-phase are shown in Figure 6. After irradiation, all cell 
lines show a significant higher percentage of cells in G2-/M-phase compared to the non-
irradiated cells. Additionally, the A-T cell lines show a significant higher increase of cells that 
are arrested in the G2/M phase after irradiation compared to the controls (p = 0.4*10-3) and 
the c.7271T>G cell lines (p = 0.58*10-3).  
 
Figure 6: Percentage of cells arrested in G2/M phase after irradiation with 3 Gy (four cell lines per group) 
(*p≤0.05, (one-way ANOVA with subsequent Tukey´s post hoc T-test)) 
 
5.4. Analysis of chromosomal breaks after irradiation with 3 Gy 
Chromosomal breaks are one of the key molecular findings in A-T patients. To measure the 
chromosomal breaks, a control, an A-T, and a c.7271T>G cell line were irradiated with 3 Gy or 
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mock-irradiated followed by a resting step in the incubator. Afterwards all cell lines were 
incubated with colcemid to arrest most of the cells in the metaphase stage and to prevent 
them from proceeding to the subsequent anaphase stage. After fixation the cells were 
dropped on a slide and stained with Giemsa. Metaphases were analysed and all chromosomal 
breaks were counted. Figure 8 shows an exemplary metaphase from each cell line (control, A-
T, and c.7271). Chromosomes show their characteristic banding and chromosomal breaks are 
highlighted with red circles. For the control cell lines, 26 metaphases were analysed and 20 of 
them showed no chromosomal breaks. There were five metaphases with only one 
chromosomal break and one metaphase with two breaks. Thirty-two metaphases were 
analysed for the cell lines derived from A-T patients. They showed a much higher frequency 
of chromosomal breaks compared to the controls. Thirteen metaphases had no chromosomal 
breaks, 10 metaphases showed one break per metaphase, seven metaphases two breaks per 
metaphase and one metaphase each had three and four breaks per metaphase, respectively. 
For the cell lines from the breast cancer patients harbouring the c.7271T>G variant, 23 
metaphases were analysed. Twelve of them showed no chromosomal breaks, seven had one 
break per metaphase, three metaphases showed two breaks and one metaphase was found 
with four chromosomal breaks per metaphase. Therefore, the number of chromosomal breaks 
per metaphase were higher in the A-T cells and c.7271T>G cells, respectively, compared to the 
control cell line. 
 
Figure 7: Exemplary metaphases stained with Giemsa showing chromosomal breaks (indicated by red circles) 
 
 
breaks/metaphase Control cells A-T cells 7271T>G cells 
0 20 13 12 
1 5 10 7 
2 1 7 3 
3  0 1 0 
4  0 1 1 
 
Table 11: Number of analysed metaphases and chromosomal breaks per metaphase in all cell lines 
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5.5. Comparison of different nuclei enrichment protocols  
To further investigate the effect of different mutations in the ATM gene upon the cellular 
response to ionizing radiation, two-dimensional fluorescent gel electrophoresis (DIGE) was 
carried out. However, whole cell lysate represents a too complex mixture for analysis. Further, 
the main response machinery for ionizing radiation-induced DNA repair is located in the 
nucleus. Therefore, a protocol for cell lysis and nuclei enrichment has to be carried out, for 
which three different protocols were tested, followed by Western Blot analysis to determine 
the purity of the subcellular compartment. Western blotting, or immunoblotting is commonly 
used to identify a specific protein of interest using the specificity of the antigen-antibody 
interaction. This method was introduced by Towbin and colleagues (Towbin et al. 1979).   
All three protocols were tested with a control cell line and the subcellular fractions were 
collected to determine the purity of each fraction by using specific antibodies for proteins 
common in this subcellular compartment. Lamin A is a component of the nuclear protein 
complex and different lamins form a two-dimensional network along the inner surface of the 
inner nuclear membrane. Therefore, Lamin A can be used as a specific antibody for the nuclear 
fraction. Phosphoglycerate kinase (PGK) is a glycolytic enzyme that catalyses the conversion 
of 1,3-diphosphoglycerate to 3-phosphoglycerate and ATP. Due to its function in glycolysis this 
protein is located in the cytoplasm and serves as a marker for the cytoplasmic fraction. The 
protein calreticulin is located in the endoplasmic reticulum (ER) and binds to misfolded 
proteins after translation of their mRNA to their amino acid structure. It prevents these 
proteins from being transported to the Golgi apparatus. Additionally, calreticulin binds 
together with calnexin to certain N-linked oligosaccharides on growing nascent chains.  
All three protocols showed an enrichment of the nuclear fraction. However, the protocol of 
Collas et al. (Collas P.) shows only a small amount of nuclei enriched in this subcellular fraction 
and also less cytosol. With the protocol of Hoppe-Seyler (Hoppe-Seyler et al. 1991) the 
enrichment of nuclei is also insufficient whereas the enrichment of the cytosolic fraction was 
effective. The best results were obtained with the protocol by Rascle (Rascle et al. 2003). The 
Western Blot analysis shows a sufficient enrichment of nuclei in the subcellular fraction, which 
is not contaminated by cytosol. Nevertheless, the purified nuclear fraction contains 
compartments of the endoplasmatic reticulum (Figure 8). The membranes of the endoplasmic 
reticulum are connected to the outer nuclear membrane. Therefore a slight contamination of 
endoplasmic reticulum has to be accepted for intact nuclei.  
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5.6. 2-D Fluorescence Differential Gel Electrophoresis (DIGE) of 
nuclei enriched fractions  
Proteome analysis is a direct measurement of a complex protein network in terms of the 
presence and relative abundance of different proteins. Therefore, two-dimensional 
fluorescent gel electrophoresis (DIGE) was carried out using nuclei-enriched fractions. DIGE 
was first described in 1975 by O’Farrell (O'Farrell 1975).  
The general workflow of two-dimensional gel electrophoresis is a two-step process. After 
sample preparation the first dimension – the isoelectric focusing - is carried out, where the 
proteins will be separated on the basis of their isoelectric point (PI). The PI is the pH at which 
a protein carries no net charge and will not migrate in an electric field. After an equilibration 
step, to reduce disulphide bonds the proteins are separated due to their molecular weight 
(MW) in the second dimension using SDS gel electrophoresis.  The use of different fluorescent 
dyes allows multiplexing of samples on a 2D gel, shows a good sensitivity and linearity and in 
combination with computer-assisted image evaluation systems it allows a quantitative and 
qualitative examination of the proteome.  
For this approach all non-irradiated samples were labelled with Cy5, all irradiated samples 
were labelled with Cy3 and a combination of non-irradiated and irradiated sample was used 
as a standard mixture and was labelled with Cy2. After the computer-assisted comparison 
(irradiated vs non-irradiated in each group) all significantly regulated spots were evaluated, 
followed by silver staining of the gels and the picking of all regulated spots. These spots were 
washed, destained and analysed by mass spectrometry (Figure 9). 
 
 
Lamin A  
(nucleus) 
PGK  
(cytosol) 
N C N C N C 
Calreticulin  
(ER) 
Collas et 
al., 1998 
Rascle et 
al., 2003 
Hopper-Seyler 
et al., 1991 
Figure 8: Western Blot analysis showing the different analyses for each subcellular fraction. 
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In the control cell lines 43 spots were significantly regulated and all spots could be detected 
on the silver stained gel. Out of these 43 spots 64 proteins could be identified, including 44 
nuclear proteins. In the cell lines derived from A-T patients, 63 spots were significantly 
regulated and picked on the silver gel. 43 proteins were detected – 16 nuclear proteins – in 19 
analysed spots. For the cell lines derived from breast cancer patients heterozygous for the 
c.7271T>G variation 42 significantly regulated spots were evaluated. But only 30 spots could 
be detected on the silver gel. In 26 spots were 43 proteins detected – 21 nuclear proteins (Fig. 
10). Due to low protein concentration it is not possible to detected proteins in every picked 
spot.  
M
2
1
Significantly 
regulated spots: 
43 (controls) 
63 (A-T patients) 
30 (BC patients) 
Destaining and  
digestion of  
gel spots 
Nano-HPLC-MS/MS analysis 
Controls / A-T / 
7271 BC 
IR (Cy3)/noIR 
(Cy5)/IS(Cy2) 
Figure 9: DIGE Workflow 
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5.7. SWATH analysis  
Various so-called „data-independent acquisition“(DIA) methods for quantitative bottom-up 
proteomics approaches have gained wide popularity through the last years (Hu et al. 2016). 
These approaches yield more comprehensive data sets and avoid the „missing data problem“ 
(Roderick J. A. Little, Donald B. Rubin 2002) typically associated with data-dependent 
approaches and also 2D-PAGE-based analyses. Using the DIA-method „SWATH“(Sequential 
window acquisition of all theoretical fragment-ion spectra) (Gillet et al. 2012), it was possible 
to quantify 1,700 proteins over the entire sample set by targeted extraction. Moreover, the 
methodology allows to re-question the measured data set concerning further, currently not 
detected proteins by enlarging the used library by future experiments.  
SWATH-mass spectrometry is a shotgun proteomic method to quantify proteins. Therefore, 
protein samples are digested proteolytically into a highly complex peptide mixture prior to LC-
MS/MS-measurement. The SWATH-analyses can be divided into two different steps – the 
library generation and the targeted extraction of quantitative data. For the first step a data-
dependent acquisition is used to identify as many peptides/proteins as possible from the 
proteolytically digested complex sample. Therefore, the mass spectrometer measures 
throughout the entire LC-gradient repeatedly the following composition: Firstly, the most 
intensive signals from a Full-MS-scan (e.g. TOP20) are selected for subsequent highly selective 
isolation and acquisition of respective MS/MS-spectra. In a second step these MS/MS-spectra 
are used to identify as many peptides as possible by database searches. However, this method 
is not suitable for quantification due to the high undersampling rate. But it could be used to 
generate a library of peptide identities, respective retention times and MS/MS-spectra and 
these data can be used for targeted extraction of MS/MS-signal intensities from subsequent 
SWATH-runs. During these SWATH-runs the mass spectrometer repeatedly measures MS/MS-
controls
43/43 spots picked
27 spots analysed
(proteins with >2 
peptides)
64 proteins
44 nuclear proteins
A-T
63/63 spots picked
19 spots analysed
(proteins with >2 
peptides)
42 proteins
16 nuclear proteins
7271 BC
30/42 spots picked
26 spots analysed
(proteins with >2 
peptides)
43 proteins
21 nuclear proteins
Figure 10: Overview of detected, picked and analysed DIGE spots 
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spectra of multiple wide precursor windows (e.g. 25 m/z per window) scanning the entire 
mass range relevant for shotgun proteomic analyses (e.g. 400-1,250 m/z). As several peptides 
may be contained within a distinct window and thereby fragmented in parallel, the respective 
MS/MS-spectra are highly complex and not suitable for identification by database searches. 
However, the data from the library facilitates targeted extraction of MS/MS-fragment 
intensities and assignment to the respective peptides. 
The Venn diagrams are showing the significantly regulated proteins in the SWATH approach 1 
hour and 6 hours after irradiation with 3 Gy vs. mock-irradiation for all three groups (controls, 
breast cancer patients harbouring the c.7271T>G substitution, and A-T patients).  
 
BC 
BC 
Figure 11: SWATH Venn diagram of all significantly regulated proteins 1 hr 
after irradiation with 3 Gy versus mock-irradiation  
Figure 12: SWATH Venn diagram of all significantly regulated proteins 6 hr 
after irradiation with 3 Gy 
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The number of proteins that overlap between the different groups are very small, which can 
be explained by the fact that the individual samples of the breast cancer patients show a high 
variance. Interestingly, one protein – that was already described in the regulation of DNA 
mismatch repair (MMR) - showed a significant regulation after irradiation with 3 Gy. MSH6 
showed a significant upregulation in the control cell lines 1 hour after irradiation compared to 
the cell lines derived from breast cancer patients carrying the c.7271T>G missense 
substitution and the cell lines derived from A-T patients.  
For all proteins that were found in the SWATH approach, a GO-Enrichment analysis using 
DAVID v6.8 was carried out (Huang et al. 2009a, 2009b). Therefore all detected proteins were 
ranked according to their p-values and analysed to reduce these large protein lists into 
functionally related groups and to help to unravel the biological content of this data set. 
Beside significantly enriched protein groups that are involved in the regulation of 
metabolic/homeostatic cellular processes, transcription regulation and the regulation of 
cyclin-dependent protein serine/threonine kinase activity also a protein group involved in cell 
cycle control and different kinds of DNA repair pathways showed a significant enrichment at 
both 1 hr and 6 hrs after treatment; regulated proteins from this group are given in Table 12.  
 
Accession Gene Protein 
Regulation upon 
irradiation1 
Involved in process 
WT BC AT 
 
Q92878 RAD50 DNA repair protein RAD50 ns - - DSB 
O60870 KIN DNA/RNA-binding protein KIN17 ns ns - DSB 
P13010 XRCC5 X-ray repair cross-complementing protein 5 + ns ns DSB 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 - ns ns DSB 
Q29RF7 PDS5A Sister chromatid cohesion protein PDS5 homolog A + ns ns DSB 
P49959 MRE11 Double-strand break repair protein MRE11 + ns ns DSB 
P09874 PARP1 Poly [ADP-ribose] polymerase 1 ns ns - BER 
Q9NWY4 CD027 Histone PARylation factor 1 ns ns - BER 
Q99459 CDC5L Cell division cycle 5-like protein + ns ns NER 
Q01831 XPC DNA repair protein complementing XP-C cells ns ns - NER 
P15927 RFA2 Replication protein A 32 kDa subunit ns ns - DSB, NER, BER 
P18858 DNLI1 DNA-Ligase 1 ns ns - all kinds of DNA repair 
Q9Y295 DRG1 Developmentally-regulated GTP-binding protein 1 - - ns Cell cycle arrest 
1Regulations observed after 1 h are underlaid in grey. 
+: significantly up-regulated 
 
-: significantly down-regulated 
 
Table 12: DNA repair proteins 
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5.8. Targeted analysis using Western blotting 6 hours after 
irradiation vs. non-irradiation 
Western Blot analyses were carried out for ATM, phosphorylated ATM (pATM) and one of the 
downstream targets of ATM – p53 and phosphorylated p53.  
Western Blots showed no significant regulation after irradiation compared to the non-
irradiated cell lines and compared between all different cell lines. However, a tendency is seen 
for p53, pATM and ATM. p53 is upregulated in the control cell lines compared to the A-T and 
breast cancer cell lines and pATM is slightly upregulated in the controls and breast cancer 
patients compared to the A-T patients. Interestingly, ATM is downregulated in the control cell 
lines compared to the A-T and breast cancer cell lines (Figure 13).  
 
Figure 13: Western Blot analysis for ATM, pATM, pp53 and p53 six hours after irradiation or mock-irradiation 
(*p≤0.05; four cell lines per group) 
 
A literature search lead to the hypothesis that there might be an export of a small fraction of 
ATM from the nucleus to the cytosol in a NEMO-dependent manner (Miyamoto 2011). 
Therefore, the cytosolic fraction was analysed by Western Blot analysis for ATM. However, 
there was no ATM protein detectable in the cytosolic fraction (Figure 14).  
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Additionally, based on the publication of Miyamoto in 2011, Western blot analysis with the 
nuclear and cytosolic fraction were carried out for NEMO and phosphorylated NEMO 6 hours 
after irradiation or non-irradiation. However, no significant regulation was detectable.  
 
 
Figure 15: Western Blot analysis for NEMO and pNMEO in the nuclear fraction 
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Figure 14: Western Blot analysis for ATM in the nuclear and cytosolic fraction of one cell line from each group 
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5.9. Western Blot analysis for ATM, phosphorylated ATM and 
downstream targets at different time points 
For further investigation the activation of ATM and its downstream targets in DNA damage 
response after irradiation Western Blot analysis was carried out with one control cell line and 
cells were harvested at different time points (0.5 hrs/1 hr/ 1.5 hrs) after irradiation. Figures 
15 to 17 show the results of this timeline experiment in comparison to the 6-hour time point. 
Because only one control cell line was used for this experiment a standard deviation could not 
be calculated.   
For ATM there is a slight downregulation from 0.5 hrs to 6 hrs detectable and the 
phosphorylated ATM shows clearly the highest fold change directly after irradiation at the 0.5-
hrs time point (Figure 16).  
 
Figure 16: Western Blot analysis for ATM and pATM in the nuclear fraction  
 
The downstream targets of ATM – the phosphorylated p53 and SMC1A – are illustrated in 
Figure 17. Phosphorylated p53 is upregulated 6-fold direct after irradiation (0.5-hrs time point) 
and shows the highest regulation at the 1-hr time point (14-fold change). The phosphorylated 
SMC1A shows the highest upregulation at the first time point (0.5-hrs with a six-fold change), 
which decreases slightly over time.  
 
0
0,5
1
1,5
2
2,5
3
3,5
4
ATM pATM
Fo
ld
 C
h
an
ge
 IR
/n
o
IR
ATM/pATM different timepoint after IR
0.5 hrs after IR 1.0 hrs after IR 1.5 hrs after IR 6 hrs after IR
  
57 
 
 
Figure 17: Western Blot analysis for pp53 and pSMC1A in the nuclear fraction 
 
An additional Western Blot analysis for NEMO and phosphorylated NEMO shows an 
upregulation of NEMO and pNEMO in the nuclear fraction at the 1-hr time point, followed by 
a slow downregulation over time. Interestingly the Western Blot analysis for pNEMO in the 
cytosolic fraction shows a very high upregulation at the 1.5-hr time point compared to the 
earlier time points and the 6-hr time point (Figure 18).  
 
Figure 18: Western Blot analysis for NEMO and pNEMO in the nuclear and cytosolic fraction at different time 
points  
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5.10. Western Blot analysis 1 hr after irradiation for ATM, 
phosphorylated ATM and its downstream targets  
Based on the time point experiment all cell lines were cultured again and harvested 1 hour 
after irradiation/non-irradiation. Western Blot analysis was carried out for ATM, 
phosphorylated ATM and the downstream targets in the DNA damage response machinery 
(pp53, pSMC1A and pNBS1). Figure 19 shows all Western Blot analyses at the 1-hour time 
point.  
After DNA damage, ATM dimer separates into monomers. These monomers will be 
phosphorylated and the activated ATM is able to phosphorylate and activate downstream 
targets. pATM is not detectable in all cell lines derived from A-T patients and is upregulated in 
all other cell lines after irradiation with 3 Gy.  
One of the downstream targets of ATM is p53. pp53 is highly upregulated in the control cell 
lines as well as in the cell lines derived from breast cancer patients with the c.7271T>G variant 
(15-20 fold). In contrast, the cell lines derived from A-T patients with common A-T mutations 
and from the patient harbouring the c.7271T>G variant in a homozygous state show only a 
slight upregulation (1-2 fold). The cell line with the c.7271T>G variant in a homozygous state 
was kindly provided by M. Taylor (University of Birmingham) and is a member of the family 
109 (109-II-6; Stankovic et al. 1998). That cell line was added to the experimental setup to 
compare an additional c.7271T>G genotype.  
Another downstream target of ATM is NBS1, which forms a multimeric complex with MRE11 
and RAD50 after phosphorylation. After irradiation, pNBS1 is significantly upregulated in the 
control cell lines compared to the cell lines derived from the A-T patients. In all other cell lines 
phosphorylated NBS1 is also upregulated after irradiation but there is no significant 
difference.  
A second downstream target of ATM is SMC1. It was shown to be a target of the ATM kinase 
with phosphorylation of Ser957 and Ser966 after ionizing radiation (Kitagawa et al. 2004). In 
the present study all cell lines show a significant upregulation after irradiation. The control cell 
lines are significantly upregulated compared to the A-T and c.7271 A-T cell lines. In addition, 
the cell lines derived from breast cancer patients harbouring the heterozygous c.7271T>G 
variation are significantly upregulated compared to the c.7271T>G homozygous cell lines.  
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Figure 19: Western Blot analysis for pATM, pp53, pNBS1 and pSMC1 in the nuclear fraction at the one hour 
time point (*p≤0.05 (one-way ANOVA with subsequent Tukey´s post hoc T-test))  
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6.  Discussion 
6.1  Cell growth, cell viability, cell death, cell cycle checkpoint and 
chromosomal breaks after irradiation with 3 Gy 
In proliferating cells, the cell cycle is an ordered series of events that cells pass through. Each 
cell cycle consists of two different stages: the Interphase, which comprises the G1, S and G2 
phase, respectively, and the Mitosis-phase (M-phase), in which a cell is divided into two 
daughter cells. At the transition between G1/S-phase, G2/M-phase and at the end of the S-
phase, there are special checkpoints controlled by cyclin-dependent kinase complexes. These 
complexes monitor the integrity of the specific cell cycle event before allowing cells to 
progress into the next phase. Different endogenous or exogenous agents can damage DNA in 
the cell and, therefore, these cell cycle checkpoints function as a control point to arrest the 
dividing cell and to determine whether the damage can be repaired and the cell can progress 
thru the cell cycle or cannot be repaired and the cell has to undergo apoptosis. Defects in cell 
cycle checkpoint recognition and/or disturbed DNA damage repair machinery can lead to an 
accumulation of DNA breaks and/or mutations in the DNA, which can lead to uncontrolled cell 
division and an increased incidence of cancer. The increased cellular radiosensitivity, cell cycle 
checkpoint defects and chromosomal instability in AT patients results in an increased risk of 
malignancy. Since 1991, it has been suggested that blood relatives of A-T patients show an 
increased risk of cancer, especially breast cancer. Taking into account all the published data, 
it seems that the ATM gene is associated with a moderate risk, but it is still not clear if ATM 
mutations can act multiplicatively and impact the response to radiotherapy.  
Therefore, ionizing radiation of lymphoblastoid cell lines derived from A-T patients, carrying 
compound heterozygous mutations in the ATM gene, or breast cancer patients harbouring the 
heterozygous c.7271T>G substitution in the ATM gene, might illustrate the impact of such 
mutations on cell growth, cell viability and chromosomal breaks. All cell lines were irradiated 
with 3 Gy or mock-irradiated and analysed to investigate cell growth by cell counting, 
differentiating between late apoptotic/necrotic or early apoptotic cell using Annexin-PI 
staining, monitoring of the percentage of cells in each cell cycle phase using PI-staining and, 
finally, counting chromosomal breaks by karyotype analysis. 
Cell counting after irradiation and mock-irradiation shows for all irradiated cell lines a 
decreasing cell count, which can be due to cell cycle arrest or an increase in apoptotic or 
necrotic cells. For further investigation, Annexin-PI staining was carried out followed by flow 
cytometry. This method could confirm, that the fraction of cells that undergo necrosis and 
apoptosis after irradiation increased in all cells lines tested. The control cell lines show a slight 
increase in necrotic and apoptotic cells, the cell lines from AT patients show a significant 
increase in necrotic cells and a slight decrease in apoptotic cells, while the cell lines derived 
from breast cancer patients show an intermediate increase in apoptotic and necrotic cells. 
Comparing all three different groups after irradiation shows that cell lines from AT patients 
show the highest percentage of necrotic cells compared to the controls, while cells from 
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breast cancer patients show only a modest increase in apoptotic cells in comparison to the 
control cell lines. The percentage of apoptotic cells was the highest in the control group, 
followed by the cell lines from AT patients and breast cancer patients, which differed only 
slightly. This experiment demonstrated that cells from AT patients, whose IR-induced DNA 
damage could not be repaired by the DNA repair machinery due to their defective ATM 
protein, undergo necrosis instead of apoptosis. Compared to that, the control cell lines show 
much less dead cells and most of them undergo the controlled cell death (apoptosis). Cells 
from breast cancer patients show a slightly higher percentage of apoptotic and necrotic cells 
compared to the controls, but do not behave anywhere like the cells from AT patients.  
DNA damage leads to an arrest of the cells at one of the cell cycle checkpoints. A PI staining 
was carried out to further investigate the effect of different ATM mutations on the cell cycle 
arrest. After irradiation all cell lines were stained and the percentage of cells in each cell cycle 
phase was measured. The irradiation with 3 Gy shows in the G1 phase no alterations in the 
control cell lines and in the breast cancer cell lines compared to the mock-irradiated cells. Cell 
lines from AT patients show a lower percentage of cells in the G1 phase after irradiation, which 
is significantly lower compared to the control (p = 0.13*10-2) and the breast cancer cells (p = 
0.43*10-4). In addition, there is no difference between the controls and the cell lines derived 
from breast cancer patients after irradiation with 3 Gy. In S phase, all cell lines show a 
significant decrease after ionizing radiation, but there is no difference between the groups 
with or without irradiation. In contrast, the G2/M phase shows a significant increase in cells 
after irradiation in the controls, the AT patients as well as the breast cancer patients. 
Additionally, there is a significant difference between the A-T cell lines after irradiation 
compared to the controls (p = 0.4*10-3) and the c.7271T>G cell lines (p = 0.58*10-3). 
Irradiation with ionizing radiation on control cell lines leads to DNA damage resulting in an 
arrest at any of the three cell cycle checkpoints and after DNA damage recognition and repair 
normal cells proceed in the cell cycle. This experiment shows that all three groups behave the 
same at the S phase and G2/M phase checkpoint, but that there are differences between the 
control and breast cancer group compared to the AT group. Cells harbouring compound 
heterozygous mutations in the ATM gene that lead to an A-T phenotype show a defect in the 
G1 checkpoint (significant lower percentage of cells compared to controls and heterozygous 
c.7271T>G cells) and a significant accumulation of cells in the G2/M phase compared with the 
control and breast cancer cell lines. A defective G1 checkpoint due to an absent activation of 
p53 was first published in 1992 by Kastan et al. (Kastan et al. 1992) and could be confirmed 
with this experiment. 
One of the common features in A-T is an accumulation of chromosomal breaks after ionizing 
radiation. Therefore, the third experiment involved Giemsa staining of the chromosomes in 
metaphase to count the number of chromosomal breaks after ionizing radiation. This had 
been already carried out and published by Waddell et al. in 2006 (Waddell et al. 2006). As in 
that paper, the number of chromosomal breaks per metaphase was higher in the A-T and 
c.7271T>G cells compared to the control cell line. Taking into account the small number of 
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analysed metaphases, the cell lines from breast cancer patients harbouring a c.7271T>G 
substitution show a higher percentage of induced chromosomal aberrations compared to the 
controls but do not behave like the cells derived from A-T patients with compound 
heterozygous ATM mutations.  
6.2. DIGE Analysis with nuclei enriched cell fractions  
DIGE analysis was carried out to further investigate differences between cell lines derived 
from A-T patients and breast cancer patients harbouring a c.7271T>G substitution, 
respectively, on the proteome level. After induction of DNA damage by ionizing radiation, 
normal cells recognize this damage, arrest at one of the cell cycle checkpoints and recruit the 
repair machinery at the DNA damage site. Due to their different mutation status in the ATM 
gene a different reaction in the DNA damage response machinery is suspected for the 
different kinds of cell lines. To proof this hypothesis, DIGE analysis was carried out for all cell 
lines, which allows a quantitative and qualitative examination of the proteome. However, 
whole cell lysate represents a too complex mixture to analyse. Since the main response 
machinery for ionizing radiation induced DNA repair is located in the nucleus, a protocol was 
carried out for cell lysis and nuclei enrichment.  An extensive literature search provided three 
different protocols, which were tested and followed by Western Blot analysis to determine 
the purity of the subcellular fractions. All three protocols showed an enrichment of the nuclear 
fraction with a different quantity and quality in enrichment and purity. The best results were 
obtained with the protocol published by Rascle (Rascle et al. 2003). The Western Blot analysis 
shows a sufficient enrichment of nuclei in the subcellular fraction, which is rarely 
contaminated by cytosol.  
For the DIGE analysis all samples were labelled with fluorescent dyes (non-irradiated with Cy5, 
irradiated with Cy3 and a combination of non-irradiated and irradiated with Cy2). After the 
computer-assisted comparison (irradiated vs non-irradiated in each group) all significantly 
regulated spots were evaluated, the gels were silver stained and all regulated spots were 
picked. These spots were washed, destained and analysed by mass spectrometry. Compared 
with the controls and the breast cancer cell lines the AT patients showed more regulated spots 
after irradiation with 3 Gy (Figure 10). Approximately half of the regulated spots could be 
analysed with mass spectrometry and 64 proteins could be identified in the control cell lines, 
42 for the cell lines derived from A-T patients and 43 proteins could be identified with this 
approach for the cell lines harbouring the heterozygous c.7271T>G variant. Although there 
was a nuclei enrichment carried out prior to DIGE analysis only a part of the identified proteins 
are of nuclear origin.  
Prefractionation can reduce the complexity of a sample and increase the visibility of minor 
proteins. Therefore, the nuclei enrichment protocol was established and used prior to DIGE 
analysis. However, the mass spectrometry results show that all samples were contaminated 
with proteins from the endoplasmatic reticulum and mitochondria. This can be improved with 
an adapted nuclei purification protocol including different sucrose gradients which increase 
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the purity of the nuclei. However, a better purification of the nuclei can result in a 
destabilisation of the nuclear membrane and, therefore, a loss of nuclear material and 
proteins. In addition, the DIGE approach can be improved to increase the resolution and, 
therefore, avoid the problem that there is more than one protein per spot. The resolution of 
the first dimension can be increased by using strips with smaller pH gradients (pH 3-6/ pH 5-
8/ pH 7-10) instead of pH gradient from 3-10. For the second dimension, gradient gels or gels 
with a lower or higher percentage of acrylamide can improve the resolution due to a different 
pore size of the gel.  
Most of the proteins that showed a significant regulation in all three groups comparing non-
irradiated vs. irradiated cells were proteins involved mRNA processing, RNA splicing as well as 
transcription factors and proteins that are part of the cytoskeleton and nuclear lamina.  
A gel spot that was significantly downregulated in both, the control and AT cell lines, contained 
the protein MRE11. MRE11 is one of three members of the MRN complex that is recruited to 
the site of DNA damage by binding active histone H2AX (yH2AX) (Jager et al. 2001; Paull und 
Lee 2005). The active MRN complex enables the recruiting of ATM at the DNA double-strand 
break as well as the activation of ATM by monomerization and autophosphorylation 
(Bakkenist und Kastan 2003). A downregulation of MRE11 after ionizing radiation can be due 
to a phosphorylation of MRE11. When proteins are phosphorylated, the protein pI will shift to 
a more acidic region, which leads to a shifting of the protein spot in the 2D gel and, therefore, 
a downregulation of the non-phosphorylated protein spot.  
Another protein that is involved in DNA damage repair is SMC1A. SMC1A is a member of the 
cohesin complex – a chromosome-associated multisubunit protein complex that is mainly 
involved in sister chromatid cohesion and, therefore, is considered essential for chromosome 
segregation in dividing cells. Furthermore, studies of cohesin mutants in yeast suggest a role 
for this complex in genome integrity and DNA repair, which was further supported by Kim et 
al., who could demonstrate an ATM-dependent phosphorylation of SMC1A after ionizing 
radiation (Kim et al. 2002). SMC1A was also downregulated in the control cell lines after 
ionizing radiation with 3 Gy. This downregulation can also be due to the shifting of the 
phosphorylated form of SMC1A in the 2D gel.  
The cell lines derived from the AT patients also showed an upregulation of RAD23B – a protein 
that is involved in Nucleotide Excision Repair (NER). RAD23B builds a complex together with 
XPC and this protein complex recognizes DNA lesions and is required for the efficient 
recruitment of all the following NER proteins (Fousteri und Mullenders 2008). It is already 
published and could also be shown in this work that AT patients accumulate a lot more 
chromosomal breaks and DNA lesions compared to controls and breast cancer patients, which 
results in a higher risk of cancer. Nevertheless, these cells are able to survive and to repair 
DNA damages which could be due to other pathways – excluding ATM – or due to other kind 
of DNA repair – for example nucleotide excision repair (NER) or homologous recombination 
(HR).  
  
64 
 
Interestingly, the control cell lines as well as the cell lines derived from breast cancer patients 
showed an opposed regulation of NONO. This protein was significantly downregulated in the 
control cell lines and upregulated in the cell lines harbouring a 7271T>G ATM substitution. 
NONO forms heterodimers with SFPQ, which are localized in nuclear bodies called 
paraspeckles and these protein complexes are involved in DNA and RNA metabolism (Shav-
Tal und Zipori 2002). In addition, Salton et al. (2010) suggested that NONO and SFPQ are early 
response proteins after DNA damage and are directly involved in DSB repair via the NHEJ 
pathway (Salton et al. 2010).  
 
6.3. Western Blot Analysis 6 hours and 1 hour after irradiation with 3 
Gy 
One of the most sensitive and specific tests for diagnosing A-T is immunoblotting of the ATM 
protein (Chun et al. 2003). About 90% of the patients do not show detectable ATM protein in 
this test, around 10% have trace amounts of protein and ~1% show normal ATM protein levels 
but no kinase activity (so called “kinase-dead”). To measure the activity of the ATM protein 
usually immunoblotting for ATM-dependent phosphorylation target proteins such as p53 
(Ser15), SMC1 (Ser966) or ATM itself (Ser1981) is employed. 
First, Western Blot analysis was carried out for ATM, phosphorylated ATM (pATM) and one of 
the downstream targets of ATM – p53 and phosphorylated p53 at 6 hours after irradiation 
parallel to the DIGE approach. After irradiation with 3 Gy the immunoblotting of ATM showed 
no significant differences between the control cell lines as well as the cell lines derived from 
A-T patients and breast cancer patients harbouring the heterozygous c.7271T>G substitution. 
But interestingly, ATM is downregulated in the control cell lines compared to the A-T and 
breast cancer cell lines. A literature search leads to the hypothesis that there is maybe an 
export of a small fraction of ATM from the nucleus to the cytosol in a NEMO-dependent 
manner (Miyamoto 2011). Therefore, the cytosolic fraction was analysed by Western Blot 
analysis for ATM, but there was no ATM protein detectable. This could be due to the small 
amount of ATM protein in a whole cell lysate and could be optimized with an 
immunoprecipitation approach against ATM. Additionally, based on the publication of 
Miyamoto in 2011 Western Blot analysis with the nuclear and cytosolic fraction were carried 
out for NEMO and phosphorylated NEMO 6 hours after irradiation or non-irradiation, but no 
significant regulation of NEMO or pNEMO could be detected.  
To further investigate the activation of ATM and its downstream targets in DNA damage 
response after irradiation, a timeline experiment was carried out. A second Western Blot was 
set up with one control cell line which was harvested at different time points (0.5 hrs/1 hrs/ 
1.5 hrs) after irradiation with 3 Gy. The activation of ATM and its downstream targets was 
much more detectable in this timeline experiment compared to the 6 hour time point. The 
phosphorylated ATM shows clearly the highest fold change directly after irradiation; at the 
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0.5-hr time point, the phosphorylated p53 is upregulated 6-fold and shows the highest 
regulation at the 1-hr time point (14-fold change), while the phosphorylated SMC1A shows 
the highest upregulation at the first time point (0.5 hrs with a 6-fold change), which decreases 
slightly over time. Furthermore, an additional Western Blot analysis for NEMO and 
phosphorylated NEMO shows an upregulation of NEMO and pNEMO in the nuclear fraction at 
the 1-hr time point, followed by a slow downregulation over time. Interestingly the Western 
Blot analysis for pNEMO in the cytosolic fraction shows a very high upregulation at the 1.5-hr 
time point compared to the earlier time points and the 6-hr time point. This experiment 
demonstrates that at the 6-hr time point most of the ATM kinase activity is already 
downregulated. Accordingly, the timeline experiment shows that the time point for the DIGE 
approach as well as the Western Blot analysis might be too late and therefore the Western 
Blot analyses were set up again.  
All cell lines were cultivated, irradiated with 3 Gy, harvested one hour after irradiation and all 
downstream targets were analysed again by Western Blot analysis. At the 1-hour time point, 
pATM is not detectable in the cell lines derived from A-T patients and is upregulated in all 
other cell lines after irradiation with 3 Gy with no significant difference between control and 
heterozygous c.7271T>G cell lines. One of the downstream targets of ATM is p53. It is highly 
upregulated in the control cell lines as well as in the cell lines derived from breast cancer 
patients heterozygous for the c.7271T>G variant (15-20 fold). Interestingly, both the A-T and 
the cell line homozygous for the c.7271T>G variant show only a slight upregulation (1-2 fold) 
However, Western blots for phosphorylated p53 show a significant difference between the 
control cell lines and the c.7271T>G breast cancer patients compared to the cell lines derived 
from A-T patients harbouring common A-T mutations or the homozygous c.7271T>G variant. 
Another downstream target of ATM is NBS1 that is significantly downregulated in the A-T cell 
lines. A third downstream target of ATM is SMC1A and in this experiment all cell lines show a 
significant upregulation after irradiation. SMCA1 is significantly upregulated in the control cell 
lines compared to the A-T and homozygous c.7271T>G cell lines. In addition, in the cell lines 
derived from breast cancer patients harbouring the heterozygous c.7271T>G variation SMCA1 
is significantly upregulated compared to the c.7271T>G homozygous cell lines. 
A comparison of these results to the literature is not easy due to an ongoing discussion about 
the behaviour of phosphorylated ATM and their downstream targets after irradiation in the 
heterozygous c.7271T>G cell lines derived from breast cancer patients. In 1998, Stankovic 
published a family (family 109) with three AT patients showing mild clinical symptoms and the 
homozygous mutation c.7271T>G in the ATM gene (Stankovic et al. 1998). The whole family 
had a history of familial breast cancer including the mother of the three AT patients, who was 
heterozygous for the c.7271T>G substitution. Stankovic postulated that the detected mutant 
ATM protein shows residual function and, therefore, leads to a ‘dose response’ effect in which 
the degree of mildness depends on the level of mutant but functional ATM protein. In 2001 
Stewart further investigated family 109 and could demonstrate a full length ATM protein for 
all cell lines derived from heterozygous and homozygous carriers of the c.7271T>G 
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substitution, a weak autophosphorylation and residual kinase activity (phosphorylation for 
p53, NBS1 and MRE11) of about 4-6% in the homozygous cell lines after irradiation with 5 Gy 
(Stewart et al. 2001). In 2002, Chenevix-Trench published a second family carrying the 
c.7271T>G ATM variant (family A) by genotyping the kConFab families – families at high risk 
for breast cancer (Chenevix-Trench et al. 2002). They analysed cell lines derived of family 109 
– with homozygous and heterozygous c.7271T>G carriers – and cell lines of family A – with 
only heterozygous c.7271T<G carriers.  After irradiation with 6 Gy, Western Blot analysis 
revealed full length ATM protein for homozygous carriers of c.7271T>G, the control cell lines 
and c.7271T>G heterozygous carriers. However, additional Western Blot analysis for 
downstream targets of ATM showed a completely abolished p53 phosphorylation in 
c.7271T>G homozygous carriers and the c.7271T>G heterozygous carriers had only 15-25 % of 
normal kinase activity – measured by p53 and BRCA1 phosphorylation - compared to normal 
controls. Based on these results, which were in contrast to the previously published results of 
Stankovic (1998) and Stewart (2001), Chenevix-Trench hypothesized that the c.7271T>G 
mutation acts in dominant-negative manner and, therefore, the wild-type enzyme is unable 
to function normally in the presence of the altered protein, due to for example competition 
effects for binding partners, substrates and regulators and therefore increases the risk of 
breast cancer in this women. In 2006, Waddell further investigated the heterozygous 
c.7271T>G carriers using microarray and Western blot analysis. Western Blot analyses of p53 
and phosphorylated p53 (Ser15) were carried out to study radiosensitivity after irradiation of 
the cell lines with 5 Gy. The heterozygous and homozygous c.7271T>G carriers showed a wide 
range of response and interestingly Waddell could not confirm the results that Chenevix-
Trench had published in 2002. In contrast to the previously reported results the 
phosphorylation of p53 at Ser15 was comparable between the wild-type cell lines and the 
c.7271T>G heterozygotes. The authors justified this discrepancy with the assumption that in 
the previous study they had used freshly established lymphoblastoid cell lines and that the 
previously postulated dominant negative effect could be influenced by a high passage 
number. Furthermore, they discussed an ATM-independent stabilization of p53 affected by 
cell culture density. Nevertheless, the heterozygous c.7271T>G carriers showed higher levels 
of p53 and phosphorylated p53, which might be due to the activation of other cellular DNA 
damage repair pathways after ionizing radiation. The use of other DNA damage pathways is 
supported by the observation that c.7271T>G homozygotes show the highest incidence of 
chromosomal aberrations, followed by heterozygous carriers and, thereafter, wild-type cells. 
The Western blot analysis carried out here could not confirm the dominant negative effect in 
the cell lines harbouring the heterozygous c.7271T>G substitution postulated by Chenevix-
Trench and Waddell. All experiments show that cell lines harbouring the c.7271T>G 
substitution in a heterozygous state act between the control cell lines and the cell lines derived 
from AT patients harbouring truncating mutations or the c.7271T>G variant in a homozygous 
state. Nevertheless, the pedigree of the family A published 2002 by Chenevix-Trench shows 
that the breast cancer is inherited with the same haplotype. One explanation could be that a 
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second mutation in another gene (located in this haplotype) acts as a modifier or an additional 
genetic factor (digenic inheritance). The haplotype could be further investigated for example 
by next generation sequencing – a new method to sequence whole exome or genomes as well 
as specific parts of the genome in a fast and cost effective manner. Additionally, the two-hit 
hypothesis – first published by Knudson 1971 could be also a possible explanation (Knudson, 
JR 1971). Knudson used a statistical model for retinoblastoma and hypothesized that one 
mutant allele is inherited and the other one is generated somatically during growth and 
therefore the cancer susceptibility phenotype is inherited in a dominant manner. Taking into 
account this hypothesis an investigation of breast tumor material by Western blot and/or DNA 
sequencing could give new insights in this matter.  
In addition the time line experiment showed that the strongest response after irradiation with 
3 Gy was at the one-hour time point. It would be interesting to repeat the DIGE approach at 
this time point to investigate the differences between all four groups (controls, AT patients, 
c.7271T>G heterozygous and c.7271T>G homozygous).  
6.4. SWATH Analysis  
In comparison to the 2D-PAGE analyses, the SWATH-MS approach yields a much larger set of 
quantified proteins with virtually no missing values. Therefore, it is suited much better for 
quantitative analyses then typical data-dependent approaches (Zhu et al. 2014). However, 
modified peptides are filtered out prior to quantification – even if they had been identified in 
the (data dependent) library runs and, therefore, the quantification in the SWATH-MS analysis 
is based solely on non-modified peptides. Additionally, protein variants such as truncated 
proteins, protein isoforms, modified proteins, etc. are often not detectable using bottom-up 
approaches (Lottspeich 2009). Therefore, the SWATH-technology is a truly orthogonal analysis 
approach to the gel-based top-down analysis conducted by 2D-PAGE. 
The combination of top-down 2D-gel-based (top-down) and shotgun-DIA-based analyses has 
clear advantages over the frequently used, mostly shotgun-based stable isotope labelling 
strategies. These methodologies - such as SILAC, iTRAQ, TMT - use the incorporation of stable 
isotope-coded moieties into proteins or peptides metabolically or by chemical means 
(Chahrour et al. 2015) and this allows the subsequent combination of two or more samples 
(so-called „multiplexing“) and therefore minimizes the problem of sample-specific losses due 
to low reproducibility of downstream separation and detection techniques. The quantification 
is based on mass spectrometry either on the MS (e.g. for SILAC, ICAT, ICPL) or the MS/MS-
level (e.g. for iTRAQ, TMT). Multiplexing with MS-level-based quantification is accompanied 
by the reduction of sensitivity due to peak splitting on the MS-level. This does not happen if 
you are using MS/MS-based techniques which typically require higher scan rates of the used 
mass spectrometers. All these methods avoid the missing-data problem (Roderick J. A. Little, 
Donald B. Rubin 2002) as long as the maximum number of analysed samples does not exceed 
the possible level of multiplexing including biological and technical replicates. If more than ten 
samples (as in this study) are to be compared, the missing data problem arises again and 
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drastically complicates data interpretation. Additionally, multiplexing using stable isotope 
labelling strategies is cost intensive and thereby limiting the number of samples/replicates to 
be investigated.  
SWATH analysis was carried out as an additional approach to analyse differences in the 
nuclear lysates one hour and six hours after irradiation with ionizing radiation. A DAVID 
analysis was carried out to cluster these proteins into functionally related groups and to help 
to unravel the biological content out of this data set. Beside protein groups that are involved 
in the regulation of metabolic/homeostatic cellular processes, transcription regulation and the 
regulation of cyclin-dependent protein serine/threonine kinase activity also protein that are 
involved in cell cycle control and different kinds of DNA repair pathways showed up. 
Interestingly the comparison of the proteins that are regulated six hours after irradiation 
within each of the three groups (controls, A-T patients, breast cancer patients harbouring the 
c.7271T>G substitution) shows that in the control cell lines proteins that are involved in DSB 
– like XRCC5, PDS5A, MRE11 and CDCL5 – are upregulated after irradiation and show no 
regulation upon irradiation in the cell lines derived from A-T patients or breast cancer patients. 
Interestingly RAD50 – one member of the MRN complex – is downregulated in the breast 
cancer and in the A-T patients after irradiation.  
However, of particular interest is the reduced regulation of proteins involved in Nucleotide 
Extension Repair (NER) and DNA mismatch repair (MMR) in the c.7271T>G heterozygous cell 
lines compared to the controls. Already in 2009, Zhang published an overview connecting 
nucleotide extension repair (NER) and DNA mismatch repair to double-strand DNA breakage 
repair (Zhang et al. 2009). Figure 1 in the paper of Zhang et al. shows the proposed linkage 
between NER/MMR and double-strand DNA repair. Interestingly, a few proteins described in 
the present work have been found to be regulated in the same direction by both DIGE and 
SWATH. They include MSH2 and MSH6, which build a heterodimeric complex with misrepair-
recognition specificity in MMR. One hour after irradiation, MSH6 is upregulated in the control 
cell lines, but significantly downregulated in the AT and in the c.7271T>G heterozygous cell 
lines. Interestingly, in 2011, Romeo et al. could show a link between ATM and the MMR 
pathway. They could demonstrate that the hMLH1 protein – that is part of the of the MMR 
pathway -  is phosphorylated at Ser406 by BRCA1 in an ATM-dependent manner (Romeo et al. 
2011). Afterwards hMLH1 is building a heterodimer with PMS2 (= MutL alpha). This 
heterodimer is recruited to mismatch pairs with damaged bases after these were recognized 
by the two other heterodimers MutS alpha (MSH2 and MSH6) and MutS beta (MSH2 and 
MSH3) and leads to the activation of the endonuclease activity of PMS2. Beside their 
involvement in MMR, Shahi et al. (2011) could also show an interaction of MSH6 with KU70 – 
one of the two key regulatory subunits of the DNA-dependent protein kinase, which plays an 
essential role in DNA double-strand break repair (Shahi et al. 2011). Shahi et al. also 
demonstrated a co-localization of MSH6 with activated and phosphorylated H2AX (γH2AX) – 
one of the downstream targets of ATM and also a key player in double strand break 
recognition. Therefore, a co-immunoprecipitation as well as Western Blot for phosphorylated 
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hMLH1 after irradiation with ionizing radiation would give new insights in this linkage between 
ATM and the MMR pathway.  
Another method to further investigate the differences in NER between control cell lines and 
the cell lines of breast cancer patients harbouring the c.7271T>G substitution would be an 
assay established by Rubbi and Milner in 2001 (Rubbi und Milner 2001). During NER, transient 
stretches of single-stranded DNA are generated and Rubbi and Milner developed a method, 
which allows single cell microscopic analysis and kinetic analysis of the DNA repair response 
based on labelling of the double stranded DNA with BrdU and using an anti-BrdU antibody to 
detect the single-stranded DNA generated in NER.  
Furthermore, interestingly another protein RAD23B – which is also connected to NER – was 
downregulated in the cell lines derived from breast cancer patients compared to the control 
cell lines as well as to the cell lines derived from AT patients. In 2009, Zhao et al. could show 
an interaction of MutS beta –the complex of MSH2 and MSH6 – with XPA-RPA or XPC-RAD23B 
in the process of DNA interstrand crosslinks (Zhao et al. 2009). Already in the DIGE analysis 
RAD23B was significantly upregulated in the cell lines derived from AT patients compared to 
the controls and the cell lines harbouring the c.7271T>G heterozygous mutation. At the 1-hour 
time point, SWATH analysis showed a significant upregulation of RAD23B in both controls and 
AT patients, which had disappeared at the 6-hr time point. This regulation of RAD23B gives an 
additional hint to a restricted function of NER and maybe MMR in the cell lines derived from 
the breast cancer patients harbouring the c.7271T>G substitution, which should be further 
investigated by Western Blot analysis of key players in this pathway and additional methods 
as described by Rubbi and Milner (Rubbi und Milner 2001).  
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